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Saccharomyces cerevisiae has provided an array of genetic tools to study unknown aspects 
of viral life cycles, supporting replication of many different RNA or DNA viruses (e.g. 
Tombusviruses or Papillomaviruses). It also provides means for up-scalable, cost- and 
time-effective production of various virus-like particles (e.g. Human Parvovirus B19 or 
Rotavirus) and as such represents a useful tool for vaccine development. To extend the 
utility of the S. cerevisiae expression system, we expressed AAV2 structural and
nonstructural proteins in yeast cells, using both authentic AAV2 and heterologous yeast 
promoters. For the first time, we described the assmbly of AAV2 virus-like particles from 
yeast-expressed AAV2 structural proteins. To do this we used AAV p40 promoter, whose 
activity in yeast cells resembled the one of yeast glycolytic promoters, resulting in the 
synthesis of the most abundant capsid protein VP3 when transformed yeast cells were 
grown on glucose as a carbon source. The expression of ther two VPs was induced from 
yeast, galactose inducible pGal1 promoter. Simultaneous production of all three VPs was 
achieved by growing the yeast cells in the medium containing both glucose and galactose, 
while their relative production levels were further optimized by varying amounts of each 
carbon source in the induction medium, followed by the fine tuning of the induction time.  
Moreover, we investigated the ability of the yeast Saccharomyces cerevisiae to carry out 
the replication of a recombinant rAAV2. When a plasmid harboring the rAAV2 genome in 
which the cap gene was replaced with the S. cerevisiae URA3 gene, was co-transformed in 
yeast with a plasmid expressing Rep68 from constitutive yeast promoter pADH, a 
significant number of URA3+ clones were scored (more than 30-fold over controls). 
Molecular analysis of low molecular weight DNA reveal d that the single stranded DNA is 
formed, in Rep68 and ITR dependent manner, and that the plasmid is entirely replicated. 
The ss DNA contained the ITRs, URA3 gene and also vector sequences suggesting that ss 
rAAV genomes were not obtained by the canonical AAV replication mechanism.  
These results could open new prospects for using yeast cell in two ways: (i) as a model 
system for studying viral and cellular factors involved in AAV2 capsid assembly and 
packaging of rAAV ss genomes; and (ii) as a novel cell factory for developing superior 
recombinant rAAV production technologies. 
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1. Introduction 
This work communicates two separate research lines that merge to open new prospective 
for adopting yeast Saccharomyces cerevisiae s a novel model-host organism for studying 
still elusive aspects of Adeno-associated virus (AAV) biology. The first part relates to 
using yeast cell expression system for production of AAV structural proteins from the 
cognate and heterologous yeast promoters and analyses the ability of these proteins to 
assemble in authentic virus-like particles (VLPs) inside of yeast cell. The second part 
investigates the aptitude of the Saccharomyces cerevisiae r plication machinery to carry 
out the replication of a recombinant AAV (rAAV) genome in the presence of yeast-cell 
expressed AAV Rep 68 protein. Together, the results obtained from these two research 
lines evaluate the properties of yeast S. cerevisiae as a novel, putative production host for 
rAAV-based vectors. 
1.1. Adeno-Associated Virus Biology and Life Cycle 
1.1.1. Virus classification and structure 
Adeno-Associated Virus (AAV) belongs to Parvoviridae family, a family of the smallest 
and the simplest viruses, whose single stranded DNA (ss-DNA) is enclosed in a non-
enveloped icosahedral capsid. These viruses infect umerous species, starting from insects 
(subfamily Densovirinae) to highly evolved vertebrates, including man (subfamily 
Parvovirinae). The vertebrate subfamily is divided in 3 genera, P rvo-, Erythro- and 
Dependo-virus, whose members share similar genomic stru ture, but are distantly related 
in sequence (~15% identity) [1]. The first two genera, Parvovirus (Canine parvovirus and 
murine one, the minute virus of mice-MVM), Erythrovirus (human prototype B19) are 
pathogens that can replicate on their own in the host cell and hence, are called 
“autonomous”. By contrast, non-pathogenic Dependoviruses, with AAV as a type-species, 
are dependent upon “helper” virus co-infection for c mpletion of their replicative cycle.  In 
particular, the name “AAV” derives from first identification of this virus, nearly fifty years 
ago, in a form of a super-infection (contaminant or a satellite virus) of the cells infected 
with Adenovirus (Ad) [2-4]. Although Ad helper functions have been most extensively 
studied (reviewed in [5]), several DNA viruses are l t r shown to provide helper functions, 
such as herpesvirus, human papillomavirus and vaccini  v rus [6-9].   
To date, over 100 AAV variants have been isolated from adenovirus preparations (stocks) 
of human and non-human primate tissues while new ones are continuously emerging; 
around 14 serotypes (variants of a known serology) have been well characterized [10, 11] 
and 11 members recognized by the International Committee for Taxonomy of viruses, 
including AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6,  avian AAV, bovine AAV, 
canine AAV, equine AAV, and ovine AAV (available at: 
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http://www.ictvdb.org/Ictv/index.htm). All these variants share similar virion structures 
and genomic organization. The virion shells of icosahedral symmetry (T=1) enclose single-
stranded, approximately 4.7kb DNA genomes, comprised of two functional regions-
terminal repeats and two viral genes (ORFs), rep and c p gene. Small, 60 subunit capsids, 
20-25 nm in diameter, are made of three types of protein subunits, VP1, VP2 and VP3. For 
attachment and internalization, all AAV serotypes ue ubiquitously expressed cell 
receptors , such as heparin sulfate proteoglycans-HSPGs (AAV2/3) [12-14] or sialic acid 
(AAV4/5) [15] (reviewed in [11, 16, 17]). However, important differences between 
serotypes consisted in the variations in amino acidcompositions of their capsid proteins, 
result in the usage of different cell-surface receptors and coreceptors, causing different cell 
entry pathways and distinct tissue tropism among serotypes. For instance, both AAV1, 
AAV5 and AAV6, utilize N-linked sialic acid [15, 18] while O-linked 2,3-sialic acid 
serves as a binding receptor for AAV4 [15]. Ever since the first infectious clone of AAV 
serotype 2 (AAV2) was established in 1982 [19], its genome has been studied most 
thoroughly among all serotypes and AAV2-based vectors quickly gained great popularity 
in gene therapy applications. Its crystal structure has been recently published [20]. 
1.1.2. AAV2 genomic organization  
For more than 25 years (since AAV2 clones were first established) all knowledge about 
AAV2 biology accumulated around the 4.7kb, single-stranded DNA AAV2 genome, 
comprising two large genes, rep and cap. All Parvoviruses share the same genome 
organization where the 5’ rep gene, located on the left half of the genome, codes for 
nonstructural proteins, essential for viral replication, while 3’ cap gene, the right half  
located, codes for structural proteins of the capsid (fig. 1.1 left). All AAV2 mRNAs 
terminates at a single poly-adenylation site at mapunit 96 [21].  
 
Figure 1.1: AAV genome organization (left) and Invert d Terminal Repeat (right). 
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Top-left part: The AAV-2 genome divided into 3 segments: rep, cap and ITRs and the nucl. positions indicated 
are: viral promoters, p5, p19 and p40, and translation l start sites of Cap and Rep proteins. Middle-left: Rep 
proteins (boxes) and corresponding mRNAs (with polyA tails). The bottom-left: p40 encoded capsid proteins 
VP1, VP2 and VP3 and regulatory protein of capsid assembly, AAP, and corresponding mRNAs. Right: 
Secondary structure of an AAV-2 ITR showing the RBEs (RBE, GAGCGAGCGAGCGCGC and RBE’, 
CTTTG) and the TRS (AGTTGG). 
ITRs. AAV genes are flanked by 145 nucleotide-long inverted terminal repeats (ITRs). 
The first 125 nucleotides of the ITR have multipalindromic structure whose 
complementary regions folds upon themselves to maxiize base pairing and forms aT-
shaped hairpin structure, while the other 20 bases, called the D sequence, remain unpaired 
(fig.1.1- right). ITRs contain all cis-acting sequences necessary for packaging, replication, 
integration of the viral genome in the host cell DNA and for the subsequent rescue from 
the integrated state (reviewed elsewhere [22, 23]).In addition, it’s been proposed that ITRs 
possess some transcriptional promoter activity, although relatively weak [24]. A key role 
of the ITR is that T-hairpin secondary structure provides 3’-hydroxyl group for the 
initiation of viral replication, thus being the origin of replication and serving as a primer 
for second-strand synthesis by a host DNA polymerase. This activity and the cis-acting 
ITRs’ function in integration necessitate, in trans, activity of the two large Rep proteins, 
Rep78 and 68, which specifically bind at the Rep binding elements, RBE and RBE’ of  
ITRs  and nick in a strand- and site-specific manner (endonuclease activity) at the terminal 
resolution site, TRS located downstream of RBEs [22]. 
The rep gene = rep ORF, by the use of two promoters, p5and p19 (map units 5 and 19), 
encodes four nonstructural proteins, longer Rep78/-68 and shorter Rep52/-40, respectively, 
designated by apparent molecular weights. Rep68 and 40 differ from Rep78 and 52 due to 
an alternative splicing which replaces 92 residue amino-acid element in the later ones with 
9 element in the former ones, while amino-acid sequence in the central portion of the gene 
is identical for all Rep proteins, translated from the same ORF (fig.1.1-left). Rep proteins 
are involved in a number of processes of viral life cycles , starting from the control of  viral 
gene expression, over regulation of AAV-2 DNA replicat on (reviewed in [22, 25]). Large 
Rep proteins, Rep 78 and 68,  perform the activities required for AAV DNA metabolism 
and site-specific integration [26-28] by means of their specific site-specific DNA binding 
and endonuclease activities as well as nonspecific ATP-ase and helicase activities, 
common to all four Rep proteins [29-33]. Large Rep proteins coordinate the viral gene 
expression mainly by transactivation of p19 and p40 romoter and repression of p5 
promoter, both through the interaction with the RBEs in the TR and within the p5 promoter 
[34]. Repression of p5 by Rep68 and 78 is well described during productive infection, 
when the presence of helper proteins enable its derepr ssion and consequential activation 
of the other two AAV promoters [34-37]. Conversely, during latent infection, AAV 
transcripts are not detected [38], suggesting that p5 repression may be attributed to the 
negative effect of some cellular factors such as YY1 [39]. Besides, large Rep proteins have 
been shown to affect the expression of various cellular and viral genes although the exact 
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level of action is often unknown [40-43]. Moreover, inhibition of the cell proliferation or 
S-phase arrest by Rep 78 is the activity mainly associated with the protein’s ability to 
induce cellular DNA damage in the cell [44, 45].  Probably related to its ability to arrest 
the cell cycle, Rep has been shown to promote p53-independent apoptosis [46]. Finaly p19 
promoter products, Rep 52 /40 play an essential role in the generation and accumulation of 
ss progeny genomes used for packaging in preformed capsids [47, 48]. 
Cap gene. For more than 25 years it was believed that AAV2 cap gene = cap ORF, where 
three capsid proteins VP1 (87 kDa), VP2 (73 kDa) and VP3 (62 kDa), with common C-
terminus, are generated from the same p40 promoter and overlapping sequences in a single 
ORF (ORF1). Only recently, a new AAV2 gene product has been identified to derive from 
the alternative ORF2 of the cap gene, coding for a nonstructural viral protein involved in 
promotion of capsid assembly [49] (Fig.1.1-left, bottom part). The relative ratio of single 
protein subunits in mature virions is approximately 1:1:10 for VP1, 2 and 3 respectively, 
reflecting the intracellular stoichiometry of the three VPs inside the producing cell. This, in 
turn, is regulated on transcriptional and translational level. The two splicing events use the 
same splice donor site, but two different acceptor splice sites, among which the one closer 
to p40 promoter is poorly used, resulting in lower abundance of VP1 coding mRNA and 
thus, lower intracellular VP1 protein level. VP2 and VP3 are translated from the shorter 
mRNA whose greater abundance is due to the use of conventional splice acceptor site. 
Lower intracellular level of VP2 is the result of the poor translation initiation from 
uncommon ACG initiator, while high expression of VP3 protein owes to the usage of 
common AUG initiator in the favorable Kozak context [50, 51]. 
Although little is known about AAV capsid assembly in vivo, generally accepted concept 
of AAV virion assembly suggests the two step mechanism where empty capsids are firstly 
formed into which singles stranded DNA genomes are then introduced [52]. This concept 
is based on early studies which demonstrated that Cap protein localized in the punctuate 
nucleolar structures in the absence of Rep or AAV DNA [36, 53]. The nucleolus may 
provide factors/chaperones that help assembly process, the notion further supported by the 
discovery of two nucleolar proteins, nucleolin and nucleophosmin, found to associate with 
AAV capsids in vitro [54, 55]. The recent finding  of Sontag et al. complemented this 
concept, showing that a newly identified AAV protein, AAP,  not only stimulates transport 
of VP proteins to the nucleolus, but also, in some way, promotes the assembly process 
itself [49]. 
1.1.3. Productive (replicative) and latent AAV virus infection 
Viral entry and trafficking to the nucleus. On their way to the nucleus where AAV2 has 
to deliver its genome in order to start replication or latent integration, virions have to pass 
multiple barriers: receptor binding, cell entry, intracellular trafficking, endosomal release, 
viral uncoating or nuclear entry. AAV2 infection on the cellular level starts with multiple 
contact with glycoprotein receptor (HSPG), the primary receptors for AAV2 binding, and 
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is further assisted by various coreceptors that are thought to be essential for its 
internalization and first post-internalization events (reviewed in [56]). These include: 
fibroblast growth factor receptor-1 [57], hepatocyte growth factor receptor [58], ανβ5 and 
ανβ1 integrin [12, 59] and the 37/67 kd laminin [60], that act as co-receptors.  It’s currently 
believed that virions enter the cell by endocytosis in a clathrin & dynamin-dependent 
process, facilitated by integrins and other coreceptors, and are rapidly transported toward 
perinuclear area via endosomal compartment: through early, late, recycling endosomes and 
lysosomes [56, 61]. When and how exactly, endosomal release occurs is still under 
investigation and is thought to be cell type specific [11]. However, recent studies have 
identified certain capsid components necessary for subcellular trafficking, thought to be 
prone to conformational changes and critical for passage from one cellular compartment to 
another. In particular, higher acidity of endosomes is thought to trigger a capsid 
conformational change which brings out to the capsid surface two functional regions 
located near the N termini of VP1 and VP2 (stretches of hydrophilic, basic regions-BRs), 
hidden in the capsid interior during assembly process. These elements, phospholipase A2 
(PLA2) domain and putative nuclear localization signals (NLS) in BRs are thought to be 
crucial for vesicular disruption followed by endosomal escape and nuclear entry, 
respectively [62-65]. Although it’s known that mutations in these regions have severe 
negative impact on AAV2 infectivity, their direct role in trafficking has not yet been 
demonstrated for AAV2. After endosomal escape, capsids can be either degraded by 
proteasomes or imported into nucleus. Although several groups have separately 
demonstrated that nucleus may be the place of AAV2 uncoating, there is still lot of 
contradiction regarding the mechanism and efficacy of virion/genome import into the 
nucleus, being the focus of current investigations (reviewed in [11]). Once inside the 
nucleus, AAV will undergo lytic or latent life cycle depending on the physiological state of 
the host cell, permissive or non permissive cellular environment for AAV productive 
infection as reviewed in the Figure 1.2. 
 
Figure 1.2: 
AAV life cycle 
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Replicative cycle. Infection with another virus (one of above listed AAV helpers) or 
genotoxic stress caused by various physical and chemi al agents are the factors that 
determine the permissive cell-state that support conversion of single-stranded AAV2 
genome to a duplex DNA. This is done by the host DNA polymerase acting on the 3’ end 
of the viral ITR. The resulting incomplete double-stranded ds-monomer (the form with the 
priming ITR closed in a hairpin and the other one replicated) is transcriptionally competent 
thus yielding Rep78/68 proteins, which are necessary to bind RBE and RBE’ of priming 
ITR and make a nick at TRS site, allowing ITR to unwind and the synthesis of ds-
monomer can be completed (schematically presented in the fig. 1.3). Ds-monomer is 
essential molecular form both for viral protein expression and for second round of self-
priming replication which will generate double-stranded DNA dimer molecules by strand-
displacement mechanism.  
 
Figure 1.3: Mechanism of AAV DNA replication. 
Letters indicate specific sequences in the inverted t rminal repeats (AA’, B-B’, C-C’, D-D’ denote 
complementary sequences). Input viral DNA is in black and newly synthesized DNA in red. The arrow 
indicates the 3’OH available as a primer for DNA synthesis. TRS: terminal resolution site.   
The two most abundant replicative intermediates, replicating-form RF- monomer and RF-
dimer serve as reservoir of ss viral DNA which, at some point, is displaced from these 
templates, probably along with ss DNA encapsidation in preformed capsids. AAV capsids 
package both positive (+ polarity) and negative DNA strand (- polarity) with equal 
efficiency (reviewed elsewhere: [17, 22, 48]). 
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All the steps involved in AAV DNA replication have been reproduced in cell/free systems 
using over-expressed recombinant Rep proteins [66, 7]. These studies further 
strengthened the concept that in the presence of Rep, AAV replication can rely mostly, if 
not uniquely, on direct help from cellular factors, since purified cellular proteins, such as 
replication protein A (RPA), replication factor C (RFC), proliferating cell nuclear antigen 
(PCNA), minichromosome maintenance (MCM) proteins, and DNA polymerase δ (Pol δ), 
were sufficient to replicate the AAV genome in vitro. Studies conducted on the 
contribution of helper viruses to AAV replication are important not only to identify helper 
activities that can be used to produce recombinant AAV vectors but also to understand 
how AAV adapts its replication strategy to the helper virus and to the nuclear environment 
in general. 
Adenovirus (Ad) helper functions have been most extensively studied among AAV 
helpers and four of its proteins: E1A, E1B, E2A, E4orf6, as well as one virus-associated 
RNA (VAI RNA), have been identified as indispensable for AAV replication. These Ad 
functions help AAV productive life cycle by stimulating viral gene expression and by 
enhancing AAV genome replication, mainly indirectly (reviewed in [5]). The E1A gene 
product relieves repression from AAV p5 promoter, probably through direct binding of the 
YY1 element [39]. Similarly, the Ad DNA-binding protein (DBP), the E2a gene product, 
was reported to be able to activate transcription fr m the p5 promoter [68]. Moreover, 
early studies showed that Adenovirus DBP protein is able to modestly enhance the 
processivity of AAV genome replication in vitro [69]. The E4orf6 gene has been shown to 
be essential for replication on several levels. First, t was demonstrated that its product can 
overcome the rate-limiting step of second-strand synthesis of the single-strand virus 
genome [70]. More recently, it was shown that the ad novirus proteins E1b55k and E4orf6 
can stimulate AAV genome replication by degrading the cellular Mre11/Rad50/Nbs1 
(MRN) complex that restricts AAV genome replication during adenovirus coinfection 
[71,72]. The function of the virus-associated RNA in AAV DNA replication remains 
somewhat elusive and has been suggested as a transla ional enhancer of AAV RNAs [73].  
Herpes Simplex Virus type 1or 2 co-infection with AAV results in AAV titers similar to 
those obtained in the presence of Ad and the very first studies in this field also indicated 
that this virus enabled more rapid AAV life cycle than the one with Ad [5, 6], which was 
later confirmed in experiments with recombinant AAV plasmids [74]. Early studies 
showed that the HSV-1 helicase-primase (HP) complex (UL5/8/52) and DBP (ICP8) were 
sufficient to replicate rAAV-2 plasmids [75] and it was later shown that the helicase 
activity, but not primase activity, of HP complex was required for this effect [76]. More 
recently, a comprehensive study of HSV-1 helper activities demonstrated that the HSV-1 
immediate-early proteins ICP0, ICP4, and ICP22 could stimulate rep gene expression and 
that HSV-1 DNA polymerase encoded by UL30, along with its associated processivity 
factor (UL42), although not strictly required, significantly increased AAV replication 
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levels induced in the presence of the HP complex and ICP8 [9, 77]. Only recently, a novel 
HSV1 protein has been shown to be directly associated with Rep proteins within AAV 
replication centers (RC), further demonstrating that is viral exonuclease plays a critical 
role during AAV replication by enhancing the formation of discrete AAV replicative 
forms, suitable for packaging, thus increasing the titer of infective AAV particles [78]. 
Having identified five HSV-1 factors in direct association with Rep proteins opposing to a 
single adenoviral helper protein [79], this study also points out a more direct role of HSV-1 
in AAV replication than that of adenovirus, indicating that AAV may be able to 
differentially adapt its replication strategy to a nuclear environment induced by a helper.  
Latent cycle. Under non-permissive conditions (in the absence of helper functions or 
stress) AAV genomes that reached the nucleus of the infected cell have the capacity to 
establish long-term latency by integrating into a specific locus, accordingly named 
AAVS1, on chromosome 19 (19q13.3-qter) (see fig. 1.2, right half ). Upon nuclear entry, 
initial conversion of ss AAV genomes to ds forms enables basal expression of Rep 78 and 
68, the only viral trans acting factors essential for integration, who form the bridge 
between ITR and p5 promoter- located Rep Binding Sites (RBS) on one side and the 
homologous sequences located in the AAVS1 locus on the other [22, 48, 80]. Various 
RBS-like elements have been identified in human genome, but the vicinity of RBE-like 
and TRS-like region in 33 bp region of AAVS1 make it almost identical to the analogous 
regions in ITR which probably enable viral integration via semi-homologous 
recombination between the two regions (reviewed in [17]). Another proposed model for 
imprecise integrational mechanism is based on simultaneous replication of AAV genome 
and AAVS1 region, both mediated by AAV large Rep proteins with intrinsic tendency of a 
Rep-mediated replication complex to switch template strands. In any case, if latently 
infected cells are subsequently infected with a helper virus, the AAV genome is rescued 
and re-enters the replicative phase of the life cycle [81]. However, recent studies with 
rAAV plasmids have shown that in contrast to AAVS1, replication at the viral terminal 
resolution site does not appear necessary for the integration event to occur [82] and the 
viral sequences required for site-specific integration has been identified. This element, 
designated p5IEE for ‘p5 promoter sequence residing integration efficiency element’, is 
the sole cis requirement for high-efficiency integration of AAV genome into AAVS1 [83]. 
Although approximately 0.1% of infecting wt AAV genomes integrate at AAVS1, this 
mechanism could nonetheless play a role in the natural history of the virus, and AAV 
proviruses have been identified in AAVS1 after natur l infection [84]. The wild-type AAV 
genome can also integrate at sites in the genome other than AAVS1, as demonstrated by 
the identification of a provirus on chromosome 1q31.1 in human tonsillar tissue and in 
multiple different chromosomes in vitro [85, 86]. These events were presumably Rep-
independent and thus analogous to the integration of rep-deficient vectors described in the 
next section. Remarkably, latent AAV genomes have be n detected in various tissues 
derived from humans and non-human primates, including bone marrow, brain, spleen, 
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colon, heart, liver, lymph node and kidney (reviewed in [87]). While the presence of these 
latent genomes is consistent with integrated proviruses, in some cases episomal genomes 
may also persist for prolonged periods [88]. A simpl fied scheme of the latent AAV 
infection is shown in the figure 1.2, right part.  
1.2. AAV-based vectors in gene therapy 
1.2.1. Brief introduction to gene therapy  
Gene therapy uses variety of nucleic acids as therapeutic agents (“genes as drugs”). 
Depending on the desired function and the disease profile, the therapeutic can be in a form 
of protein coding DNA /non-coding DNA / RNA or analogous molecules, such as: mRNA 
targeting antisense oligos, siRNA, decoys, ribozymes etc. Their usage is wide, starting 
from prevention (e.g when used as adjuvants for vaccin tion), over gene augmentation in 
acute treatments, to compensation for “genetic loss-off function” in chronic diseases. 
Moreover, therapeutic genes can provide cytotoxicity in cancer cells or be used for 
correction of endogenous genes, which presents extremely important branch of gene 
therapy yet, still limited to experimental studies in cell-culture. In each gene therapy 
approach the choice of a therapeutic gene (transgene), a target cell/organ and a delivery 
route have to be matched in the best way to provide maximal efficiency, specificity and 
persistence of gene transfer, while minimizing  toxicity  associated with: gene 
administration method and/or the transgene itself. Gene therapy uses three major routes of 
delivery: 1. ex-vivo, gene transfer is performed in laboratory, in isolated hematopoietic or 
stem cells, followed by re-administration of “transgenic” cells back into the patient; 2. In-
vivo systemic delivery (intra-venous/arterial/peritoneal); nd 3. In-vivo topical delivery, 
directly in tissues hardly reachable by systemic delivery (e.g brain, eye, joints) or where 
systemic delivery could cause unwanted effects (e.g tumors). Naked nucleic acid 
therapeutics are generally difficult to deliver and are destined to rapid elimination from the 
circulation for couple of reasons: rapid clearance by serum nucleases, lack of organ-
specific distribution and low efficiency of cellular uptake. The use of virus-based vectors is 
currently the best way for improving delivery efficiency and long term transgene 
expression; while most gene therapy strategies are coalescing around two types of viral 
vector: lentivirus vectors for ex vivo gene transfer and AAV vectors for in vivo transfer into 
postmitotic tissues [89]. Nevertheless, these viral vectors have various limitations: i) 
inherent packaging constraints limit the size of the erapeutic gene; ii) safety concerns 
related to: immunotoxicity (harmful immune response) of capsids, envelope proteins, 
residual viral genes and risks associated with high probability of mutagenic integration 
(retroviral & lentiviral vectors); iii) transcriptional silencing of integrated vectors leading 
to reduced transgene expression over time. In addition, even weak immune responses 
generated against vectors can dramatically decrease transgene expression upon re-
administration. Similarly, pre-existing (memory) immunity against common viruses in 
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human population, such as Ad and AAV is one of the main limitations of these vectors. 
Thus, it is imperative to develop efficient producing and engineering technologies to 
render the vectors capable of escaping immune recogniti n and avoid inflammation.  
(Literature used for this section: [17, 90-93]) 
1.2.2. Properties of AAV-based vectors 
Several marked features of AAV life cycle such as the ability of these viruses to infect 
non-replicating cells, capacity to integrate its provi al DNA into a specific site of the 
human genome and almost non-immunogenic nature of AAV infection, indicate how well 
these viruses adapted to long-term persistence and coexistence with the host cell without 
causing any deleterious effect. These aspects continue o inspire still growing use of AAV 
viruses in gene transfer technology. The first successful cloning of AAV2 in early 1980s 
led to more than two decades of constant effort in improving recombinant technologies for 
AAV-based vector production followed by extensive studies of unknown aspects of AAV 
biology (particularly serotype 2). So far, AAV vectors have shown therapeutic efficacy in a 
range of animal models (mice, pigs, dogs, ship etc.), owing to a number of properties 
which make them preferential with respect to other viral vectors. First of all, these  vectors 
are “gutless”, constructed by complete deletion of all viral genes, rep and cap, and 
insertion of “therapeutic” gene (gene of interest) between ITRs, which are the only viral 
cis-acting element indispensible for replication and packaging or recombinant AAV 
genomes, as long as rep, cap and helper functions are provided in trans by the packaging 
cell [94] (see fig. 1. 4, left part). Since only 300 nucleotides of viral DNA are retained in 
the vectors, the risk of their recombination with wt virus is minimal. Further, such 
“gutless” AAV vectors, deprived of the previously mentioned cis integrational element and 
trans acting integrational factors (p5IEE element and rep68/78 proteins, successively) are 
not capable of integrating their genome site-specifically. Once they enter the nucleus of a 
targeting cell, these vectors may persist in couple of molecular states (Fig. 1.4 - right part).  
 
Figure 1.4: AAV vector production and rAAV genome processing in the targeting cell nuclei 
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One common outcome is the conversion of the AAV genome to a double-stranded circular 
episome either by second-strand synthesis or complementary strand pairing [95, 96]. These 
episomes can be further converted to high-molecular-weight multimeric concatamers [97], 
formed by the recombination of monomer genomes [98], and probably are the main source 
of long-term transgene expression, particularly in non-dividing cells [85, 97]. Such a 
transductional mechanism of AAV vectors almost eliminates the risk of insertional 
mutagenesis or silencing, seen for integrating retroviral vectors. Accordingly, in the 
absence of the immune response to a therapeutic gene, or the pre-existing immunity to 
common AAV serotypes, transgene expression from AAV vectors in vivo can last for 
months or years. Such a success was specifically documented in AAV-based gene transfer 
approaches in animal models [99], which lack memory immunity to most of the human 
AAV serotypes used in these approaches. However, a la ge body of data demonstrates that 
AAV vectors can also integrate at non-homologous sites in the host genome, both in vitro 
and in vivo, either as a single-copy proviruses or concatamers [84, 87, 100]. More recent 
studies focused on analysis of large number of vector : chromosome junctions (e.g. Inagaki 
et al. characterized approx.1000 integration sites from liver, heart and skeletal muscle 
[101]) and provided insights into AAV vector integration process. The integration of AAV 
vectors occurred preferentially at specific sites, ‘hot spots’, in the genome such as: 
ribosomal DNA repeats that encode ribosomal RNAs [102, 103], CpG islands and within 
1kb of transcription start sites [101-103]; segmental duplications, satellite DNA and 
palindromes [101, 102]. Moreover, in mouse hepatocytes, around 60 % of AAV vector 
integrations occurred in active genes [103]. These int gration hot spots may represent 
regions of genomic instability and together with the evidence that AAV vectors integrates 
at chromosomal double-strand breaks [104] (generated by the endonuclease I-Sce I, or by 
treatment with etoposide and γ –irradiation), suggest the model of AAV vector integration. 
According to Deyle and Russell, these data suggest that the nonhomologous integration of 
AAV vectors is not a random event and that the preferential integration at certain sites 
presumably reflects availability of free chromosomal ends that can ligate to AAV, such as 
regions prone to double-strand breaks or other forms of DNA damage [87]. Even though a 
rare event, the nonhomologous AAV vector integration can be associated with 
chromosomal deletions and rearrangements [105], where the most concerning, possible 
genotoxic effect is the malignant transformation of a transduced cell. The majority of 
experimental data in animal models have demonstrated that AAV vectors are safe in this 
regard. Still, some convincing evidence for AAV-induced tumorigenesis derives from a 
follow up study with mice with mucopolysacharidosis VII (resulting from mutations in β-
glucuronidase) injected with the vector carrying human β-glucuronidase gene [106]. Both 
mutant and non-mutant mice injected with the same vector had an increased incidence of 
hepatocellular carcinoma (~50% compared with ~8% in controls) and showed the 
occurrence of four independent tumors containing vector proviruses in the same locus (but 
not in the surrounding normal liver tissue) suggesting hat insertional mutagenesis by AAV 
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vectors was the cancer trigger, although these loci were not previously associated with 
hepatocellular carcinoma. Besides, AAV vectors also integrate into tissues other than the 
liver, heart, skeletal muscle [101], thus pointing to the need for further research to fully 
assess the risk associated with AAV vector genome int gration into the host genome. 
(Other  literature used for this section: [16, 17, 80, 107].  
1.2.3. Strategies for improving properties of AAV2 vectors  
Albeit transduced with different efficiencies, skeletal muscle, hart, liver, brain, retina and 
lungs are the main targets for AAV2-based gene transfer approaches, while many cell 
types and relevant diseased tissues still remain non-permissive to transduction by AAV2 
based-vectors (and vectors based on other serotypes). The reasons for these differences in 
tissue transduction efficiencies go beyond the receptor choice and internalization and 
reflect cell-type related differences (limitations) at various points essential for efficient 
transgene expression, such as : viral subcellular trafficking to the nucleus, nuclear entry, 
uncoating and second-strand synthesis (reviewed in [17, 80]). The last limitation was 
partially overcome with development of self-complementary (sc) AAV vectors, which 
once in the nucleus can fold upon themselves and elicit rapid expression of a therapeutic 
gene without the need for inefficient second-strand synthesis [108]. Moreover, packaging 
of AAV2 based-recombinant genomes into capsids of other serotypes, which show 
different tissue tropism from the one of AAV2 serotype, “pseudotyping technology” 
(fig.1.5), can meliorate efficiency of transduction for some tissues, but only slightly widen 
the range of AAV2 permissive tissues [17, 109, 110].  
 
Figure 1.5: Different AAV serotypes target different groups of tissues. 
Information taken from www.aaveye.eu and Ref. [17] 
Beside pseudotyping, other similar production technologies were developed in order to 
overcome transduction limitations of AAV2 vectors and further expanding tissue tropism. 
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These technologies tend to synergistically combine properties of naturally occurring 
serotypes and further improve them by introducing certain modifications (e.g. targeting 
peptides), leading to generation of mosaic, chimeric and targeting vectors (direct and 
indirect) . The mosaic vectors are composed of mixed capsid subunits of various AAV 
serotypes [111],  while chimeric vectors are produced by domain swapping approach 
among multiple parental serotypes, involving either entire capsid loops or parts thereof or 
individual residues [112, 113]. For example, domain swapping between serotypes 1 and 2 
yielded a chimeric vector who could be purified by heparin affinity chromatography 
(purification method designed for AAV2 serotype), had increased transduction efficiency 
of muscle cells (AAV1 property) and was less efficiently recognized by anti-AAV2 
neutralizing antiserum [113]. Furthermore, genetically engineered capsids can lead to 
more restrictive targeting to a diseased tissue. Numerous groups have developed novel 
strategies to engineer “designer” AAVs tailored for better transduction of clinically 
relevant organs (reviewed in detail in ref [11, 114, 15])  These strategies can be grouped 
in “direct”, physical capsid modifications approaches or “indirect” approaches that base on 
chemical binding of targeting molecules (ligands) to the viral surface, forming a conjugate 
ideally able to retarget the capsid to a refractory cell type. Examples of such ligands are: 
bispecific antibodies [116], avidin-coupled ligands [117] or cellular receptors. In the direct 
targeting approach, targeting ligands are genetically inserted into the viral capsid proteins 
[118, 119]. The insertion site has to be chosen in a way to avoid interference with 
assembling, packaging and infectivity properties of m dified virions [120]. In this view, N-
terminus of VP1 and VP2 was shown to be a good choice f r such modifications [121]. In 
addition, conferring selective tissue targeting often demands elimination of broad tissue 
tropism, since a considerable safety issues are rais d if non-target tissues are transduced. 
It’s been observed that systemically routed AAV vectors accumulate in the liver and spleen 
(mainly associated with HSPG receptor recognition of AAV vectors), thus reducing the 
transduction efficiency in non-liver target tissues [122, 123]. Some success in combining 
vector de-targeting from liver and spleen was achieved by insertion of targeting ligands in 
positions of or close to HSPG binding domains [124, 125]. 
The aforementioned example of domain swapping between AAV1 and AAV2 serotypes 
demonstrate that the use of different AAV serotypes resent one way for avoiding vector 
clearance by pre-existing anti-AAV2 immunity to vector capsids. However, results in 
humans indicate that AAV capsid-primed CD8+T cells are likely to cross-react with 
alternate serotypes thus urging further development of new strategies for circumventing 
immunotoxicity [126]. One of possible strategies is introduction of mutations in capsid 
epitopes recognized by anti AAV2-neutralizing antibodies (A20). Mutations are either 
results of clever guesses [127] or the use of “evolutionary strategies”, where 
combinatorial libraries of mutated cap regions are subjected to high-throughput screenings 
for selection of desired characteristics [125, 126, 128]. 
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(For detailed reviews of all aforementioned strategies see Ref: [10, 11, 80, 126]). 
Two inherent limitations of AAV vectors are the small, prox.5kb, packaging capacity of 
the capsids and infrequent integration in quiescent target cell-genomes. The first limitation 
can be overcome, in a part, by skilful engineering of transgenes and their regulatory 
regions (minimizing the size) and by use of trans-splicing approach for expression of 
transgenes greater than 9kb [129]. Although rare and mostly related to chromosomal 
rearrangements, integration events point to the need for fully assessing the associated risk 
in the future. Finally, long-term expression of the therapeutic level of transgene is the 
major challenge associated with clinical usage of AAV vectors. As indicated from large 
number of AAV -based pre-clinical and phase I (less phase II and III) clinical trials, these 
challenges are tissue-specific and embrace cell-type dependant variables related to 
administration rout and predominant immune responses directed to the vector or to the 
transgene product [130]. 
1.2.4. Historical overview of current methods for AAV-vector 
production  
Extensive studies on AAV-vectors in the last decade resulted in a variety of currently 
existing methods for their production. However, therising number of AAV vector-based 
gene therapy trials that require high vector doses, over 1013 genome copies (g.c.)/kg of 
body weight [131], impose the need for creating new production technologies with better 
“yield versus cost” parameters. 
When the first foreign gene was expressed from AAV2 vectors in mammalian cells in the 
early 1980’s, the stocks of virions carrying recombinant AAV2 genome were obtained by 
transfection of Ad2 infected HEK-293 cells (a human Adenovirus E1A and E1B genes -
transformed cell line) with two bacterial plasmids, one carrying rAAV genome and the 
other one providing missing cap gene in trans [132].  Soon later, concerns surrounding the 
use of replication-competent vectors lead to elimination of rep gene form recombinant 
genomes and providing it in trans together with cap gene, while infection with Adenovirus 
was still used for providing helper functions. Frequ nt contamination of AAV2 stocks with 
Ad urged cloning of Ad genes into bacterial plasmid, thus eliminating infection [94, 133]. 
Concerns regarding generation of replication competent vectors were reduced by placing 
rep and cap genes in opposite orientations. The triple  transfection-based AAV 
production method was the subject of further improvements associated with extensive 
studies on minimal helper function requirements, leading to currently used protocols for 
HEK-293T production system which involves following components: (1) vector containing 
recombinant rAAV genome - the transgene expression cassette flanked by two ITRs 
(AAV2 derived), (2) plasmid providing Rep and Cap proteins in trans, and (3) plasmid 
containing adenovirus genes encoding E1, E2A, E4, and virus-associated RNA (VA-I 
RNA) comprising minimal requirements for inducing cell permissivity to productive AAV 
replication [5]. The next upgrading introduced to this system was placing AAV2 rep and 
cap genes together with Ad-helper genes in a single “helper” plasmid, thus diminishing 
number of transfecting constructs from three to two
for production of “pseudotyped” AAV2 vector genomes; instead of AAV2 cap gene 
sequence, the helper construct comprises of serotype
expression cassettes [134].  
Vector generation in a producing cell involves following steps: Rep and VPproteins are 
expressed from helper plasmid and the type2
from the vector genome and replicated in Rep78/68 dependent manner followed by 
encapsidation of ssDNA into preformed capsids of desired serotype (reviewed elsewhere 
[17, 135]). The vector yield from transfected HEK293 cells was further improved with fine 
tuning of Rep78-Rep52 expression level with better results obtained 
inferior to Rep52. Although advanced, the productivity of transient transfection
method (titers of viral stocks obtained) was still limited by transfection efficiency of the 
cell line utilized. So far, the best results are obtained with HEK293 cells when calcium 
phosphate precipitation is utilized for transient transfection (reviewed in 
Figure 1.6: Transient-transfection based protocols for rAAV production from HEK
The system presented is using two plasmid componen
cassette, flanked by (ITRs); plasmid encoding for: Rep, Cap and adenoviral proteins providing helper 
functions. Twenty-four hours after transfection, cells are lysed and the vectors are purified by standard cesium 
chloride ultracentrifugation. Figure reproduced from r
To overcome transfection limitations, infection
vectors are developed. Packaging cells (employing different cell lines) are infected with 
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(fig.1.6). The same procedure is used 
-specific cap and AAV2 rep 
-ITR flanked transgene cassette is rescued 





ts: 1. AAV vector itself, harboring transgene expression 
ef.[17]. 
-based protocols using recombinant viral 
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Adenovirus, Herpesvirus or Baculovirus-based vectors (reviewed in [135]), carryng both 
rAAV genome and helper functions. Although high rAAV titers were obtained with 
Herpesvirus - Baby-Hamster-Kidney cell line (BHK) double-infection system [137], this 
method is still not widely accepted. On the contrary, recombinant Baculovirus infection of 
evolutionary distant insect cells has gained lot of p pularity since originally established 
[138]. The original system consisted of three different baculoviruses: the 1st one carrying 
rep genes, the 2nd one-cap genes and the 3rd one carrying ITR flanked transgene. 
Finally, great effort has been made for creating “packaging” and “proviral”, stable cell 
lines (mammalian), considered as the best systems for scaling up manufacturing procedure. 
Packaging cell lines contain rep and cap genes integrat d in the host genome, while the 
second one contain integrated recombinant AAV genome. The best currently existed 
stable-cell line systems are based on HeLa cell-lines, but BHK and 293T cells have been 
also successful so far. Opposing the HeLa packaging cell line, the major difficulty in 
generating a 293-based AAV producer cell line is the E1A mediated activation of AAV p5 
promoter, which control AAV Rep78/68 proteins, which  are known to be cytotoxic if 
constantly expressed [46]. Thus, this difficulty is overcome by creating cell lines with 
highly inducible Rep systems [139-141]. However, a main limitation which renders stable-
cell line approach insufficiently efficient is the multi-step and time-consuming procedure. 
Due to multiple steps of transfection and/or infection and selections, several weeks to 
months are needed to produce a high-yield cell line [135, 136, 140, 141]. 
Since AAV particles are very resistant to harsh manipulation and solvents, conventional 
methods for purification of AAV vectors are based on cesium chloride density gradient 
ultracentrifugation, which provides efficient separation of empty capsids from genome 
containing virions [17] (Fig.1.5-bottom). Still, it’s been observed that longer exposure of 
particles to CsCl can cause a certain decrease in vctor infectivity, leading to development 
of alternative purification strategies. Zolotukhin et al. described the use of nonionic 
iodixanol gradients followed by ion-exchange or heparin-affinity column chromatography 
for the purification of AAV2 and other serotypes able to bind heparan sulfate [142]. 
So far the most commonly used rAAV production method, based on transient transfection 
of mammalian cells, holds one crucial limitation: the use of adherent cell cultures which 
make this methods difficult to scale-up. Growing vector requirements for large animal-
preclinical and human-clinical trials practically cannot be met with the use of adherent 
cell-solid supports, such as tissue culture plates (around 50-15 cm plates needed for 293-
cell production of 1014 rAAV particles with current transfection methods). This issue is 
being addressed with new technologies using shake flasks and bioreactor-based 
suspension cultures of HEK-293 cells, suitable for scaling-up, although expensive and 
manpower demanding [143, 144]. Aside of great improvements achieved in traditional 
production in mammalian cells, Baculovirus-Sf9 suspension culture system has been the 
subject of active optimization in the last years and hence, developed into a reliable and 
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scalable process. Although producing as much rAAV particles per Sf9 cell as per 
mammalian cells, the original system was mainly limited to small-scale production for two 
reasons: (i) it required high MOI of each of the three Baculoviruses (Bacs) for efficient co-
infection and (ii) proliferation of infected cells had to be limited due to high instability of 
rep Bac helper and the consequent loss of Rep protein expression following passage 2/3 
[145]. These deficiencies were alleviated with optimal expression of Rep78 and Rep52 
from a single polycistronic transcript and placing the Cap ORF into the same baculovirus 
expression vector (BEV), in the opposite orientation with respect to the Rep cassette [146]. 
Stabile expression of the VP and Rep proteins from c nsolidated “RepCap”- Bac was 
observed through at least six amplification passage. This enabled couple-fold increase in 
the cell-density of suspension cultures, while keeping the same particle per cell yield. 
Further advances involved optimization of feeding and growth conditions as well as 
improvements in processing protocols for efficient recovering of rAAV vectors from large 
volumes and biomass (40-100l bioreactor cultures). Currently, Bac-Sf9 system can meet 
requirements of commercializing rAAV production, offering lower production costs, high 
productivity and relatively easy scalability [147, 148].  
Efficient Rep78-dependent rAAV replication and production of biologically active vectors 
in invertebrate cells inspired us to explore the permissivity of the most simple, eukaryotic, 
single-cell organism, the yeast Saccharomyces cerevisiae, for rAAV genome replication on 
one side and AAV virus-like particles (VLPs) assembly on the other. In view of the greater 
complexity of the cell biology and genetics of metazo ns, yeast has already demonstrated 
its usefulness for virus research, which will be discussed in the following section together 
with the advantages of yeast-based heterologous expression system over the other currently 
applicable systems for foreign protein production (viral proteins in particular). 
1.3. Budding yeast, Saccharomyces cerevisiae, as a cell factory for 
viral proteins and model organism for studying virus biology  
So far, structural and nonstructural viral proteins have been expressed from practically all 
recombinant cell-expression systems, from bacteria to human cells. The producer cell 
choice depends on the characteristics of foreign protein/protein complex (e.g. VLPs) on 
one hand and from downstream applicability of the produced protein/VLPs on the other, 
such as:  
1) Basic research (e.g. Structure–function analysis [149]); 2) Biomedical applications: 
diagnostic research and seroepidemiological studies employing various pathogenic viruses; 
production of vaccines and vaccine candidates, either n a form of surface viral protein or 
peptide or multisubunit VLPs (in detail in the following sections, table 1.1); 3) production 
of VLP for nanotechnology applications (e.g. nanoparticles for DNA and drug delivery 
[150]).  
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While small scale production satisfies the needs of basic research, commercialized 
biomedical applications, designed for use in humans and animal models, demand usage of 
safe, easy to scale up and possibly, low-cost, recombinant expression systems. 
The first part of this section addresses some of the major advantages of the high yield-yeast 
expression system over other heterologous systems, underlying the notable importance of 
this organism in the field of vaccine production, mostly based on efficient VLPs assembly 
in yeast cellular background. The second part provides a brief overview of the S. cerevisiae 
permissivity to replication of many lower and higher eukaryotic viruses and of a further 
use of this phenomena in elucidating still unknown aspects of viral life cycles. Together, 
they suggest the potential of extending current usage of yeast-cell factories to production 
of viral vectors for gene transfer approaches.  
1.3.1. Cell factories for recombinant pharmaceuticals. Why yeast?  
Since the beginnings of recombinant DNA (rDNA) technologies in the late 70's, large set 
of methodological platforms have been developed for pr duction of foreign proteins of an 
important therapeutical, industrial and research values in both eukaryotic and prokaryotic  
systems. The first recombinant protein-based pharmaceutical to enter the market in early 
80’s (Food & Drug Administration of USA (FDA) approved) was human insulin derived 
from recombinant Escherichia coli. E.coli was the first microorganism used for production 
of recombinant therapeutics saving uncountable lives, albeit, this expression system was 
often facing obstacles related to frequent aggregation of overexpressed proteins, thought to 
be associated with aberrant protein folding and/or stress response of the host to the foreign 
product [151]. The attempt to produce recombinant Hepatitis Virus B small (s) surface 
antigen-sHBAg in E.coli expression system failed due to instability of the protein and its 
deleterious effect upon the host cell. In addition, this first recombinant subunit vaccine was 
abortive since it failed to induce immune response in “immunized” test animals [152]. 
Soon after, the platform of heterologous systems for expression of recombinant 
pharmaceuticals incorporated: bakery yeast Saccharomyces cerevisiae, other less common 
yeast species (Pichia pastoris, Hansenula polymorpha), mammalian and insect cells and 
more recently, transgenic plants and animals adapte to the same purpose. The preference 
in using bacterial and yeast cell-factories over th other expression platforms is hold, on 
one hand, in a simple microbial cultivation and instrumentation procedures, and, on the 
other hand, in a genetic flexibility of these microo ganisms, apt to engineering and 
manipulation [151]. Stable, autonomously replicating plasmid-based protein expression 
from high-density microbial cell cultures enabled inexpensive, controllable and highly 
scalable production of polypeptides of interest. However, the aforementioned drawbacks of 
E. coli expression platform mainly consisted in its inability or inefficiency to authentically 
process foreign proteins and introduce certain post-translational modifications (PTMs) 
present in most proteins processed by mammalian cells (e.g. glycosylation or 
phosphorylation) [153, 154]. Among PTMs, glycosylation is the most common and 
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important one, playing a crucial role in protein folding, processing, stability, final 
biological activity, tissue targeting, serum half-life and immunogenicity of the protein. 
Therefore, failures of bacterial cell in e.g disulfide bond formation, correct proteolytic 
processing and/or introduction of correct PTMs, may result in a production of insoluble, 
unstable or inactive proteins. Advances in genetic ngineering enabled some of these 
hurdles, such as protein misfolding and aggregation, o be overcome by stable introduction 
of various chaperons and foldases [154, 155]. Otherwis , yeast is generally considered 
advantageous microbial cell-based expression system ince its eukaryotic intracellular 
environment is suitable for the most of authentic posttranslational processing events, 
typical of higher metazoans (and most importantly of mammalian cells); whereas the low-
cost production from this organism is the advantage ov r higher eukaryote expression 
systems [156]. Furthermore, the long history of S. cerevisiae industrial applicability in 
brewing, winemaking and baking demonstrate the absolute absence of hazardous pyrogens, 
pathogens or viral inclusions in the final products obtained from these cells.  Accordingly, 
this microorganism has been classified as a GRAS (generally regarded as safe) [157, 158]. 
The era of its successful utilization in pharmaceutical biotechnology started already in the 
early 80’s, when the first commercialized recombinant vaccine against Hepatitis B 
(sHBAg) was made in Saccharomyces cerevisiae, soon after the production in E.coli failed 
[159]. Its wide utilization has been further improved with genetic modifications of selected 
S. cerevisiae strains, facilitated by the availability of its complete genome sequence, 
published in 1996 [160]. Subsequent sophisticated approaches of genetic engineering 
enabled manipulation of entire yeast metabolic pathw ys performing gene deletions or 
introductions of single/multiple genes, creating “improved” strains with novel 
characteristic [158]. For example, addition of humanized N-glycans of the intermediate 
mannose type or even the complex types provides the option to produce 
biopharmaceuticals with human protein modifications [161]. In the last decade, 
heterologous expression systems for biopharmaceutical production based on S. cerevisiae 
and other yeast species are given the highest commercial value [162]. In a big part this is 
because S.cerevisiae is an extensive tool-kit of plasmids for high-level expression from 
large number of wild type (wt) and artificial, regulative and constitutive yeast promoters, 
of different strengths and substrate dependences [163, 64]. Besides, new regulation 
systems continue to be added to the existing expression platform and together with a range 
of engineerized “gracious strains” [165] continue to offer more refined transcriptional- to -
posttranslational control. Shortly, yeast cell allows refined control of “when” (e.g. 
triggering expression by means of inducible promoters), “where” (intracellular 
accumulation vs. secretion) and “how much” (easily scaled-up expression) of the 
recombinant product will be obtained.  
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1.3.2. Saccharomyces cerevisiae as a cell factory for VLPs  
Since yeast derived HBV vaccine was certified for human use in early 80’s, high-yield 
production from S. cerevisiae system has been reported for large number of viral structural 
proteins derived from both prokaryotic and eukaryotic viruses. The viral 
biopharmaceuticals include: 1. surface proteins, useful candidates for recombinant subunit 
vaccines but also used for structural analysis [156]; 2. viral core and nucleocapsid proteins, 
mostly used for diagnostic tests and seroepidemiological studies; 3. authentic and chimeric 
VLPs, which are of the greatest interest to this work (1-3 reviewed in the table 1.1).  
Table 1.1: S. cerevisiae cell factory for production f “virus-like” pharmaceuticals 
Fammily & 
Genus 
Virus species  
(+1parasite) 
Downstream application 
The type of 
“virus-like” 
pharmaceuticals 
Hepadnaviridae Hepatitis B  -FDA approved vaccine; 
[159, 166, 167] 










Polyomaviridae Human papilloma virus 
(PAP) type: 6,11,16,18 
FDA approved vaccine- 
“Gardasil [169-171] 
 




Cottontail Rabit PAP 
[173] 
Polyomaviridae Human polyomavirus[174] 
Parvoviridae Human Parvovirus B19 
[175] 
Leviviridae Bacteriophage Q3[176] “Nano”-drug delivery of: 
Peptides (e.g -antigens) and 
mRNAs (vaccines) 





Reoviridae Rotavirus [179] Triple-layered 
VLPs 
Paramixoviridae Human Parainfluenza 













Menangle Virus [182] 
Tioman Virus [183] 
Measles Virus [184] 
Mumps Virus [185] 
Sendai Virus [186] 
Bunyaviridae Hantaviruses [187] 





Rhabdoviridae Rabies virus [189, 190] Surface 
glicoproteins Herpesviridae Herpessimplex virus [191] 
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In the recombinant background, conformationally authen ic VLPs are formed from the 
viral structural proteins expressed in the same cell, that spontaneously assemble into highly 
ordered structures, in absence of viral genetic material or non-structural viral proteins [184, 
192]. As mentioned above, the architectural characte istics of the particles reflect the ones 
of the native virions enabling their application in various research and medical fields: 
vaccinology, diagnostics and seroepidemiology, material science and nanotechnology. As 
shown in the table 1.1, S. cerevisiae produced VLPs have been mostly used as diagnostic 
antigens and vaccines for human and animal diseases.  
However, yeast is not the major source of existing VLPs that have been produced so far for 
more than 30 human and animal pathogenic species. Till recently, only simple VLPs have 
been efficiently produced in yeast cells. They are composed of single nucleocapsid protein 
layer or a chimeric protein assembled in one layer [193]. Among them, of the greatest 
importance are two FDA approved vaccines, currently used for human vaccination 
worldwide: against hepatitis B and against human papillomavirus type 16 and 18 (see 
table1.1).  
General advantages and current advances in yeast-cell expression technologies (discussed 
above) hold promises to overcome such challenges. Thi  was recently proved in practice 
with the first successful production of triple-layered Rotavirus-like particles in S.cerevisiae 
[179]. So far, Rotavirus like particles have been effici ntly produced from IC-BEV system 
which still gives much higher VLP titers than yeast [179, 194].  
However yeast cell offers low-cost, safe and easy to scale-up production while insect cell 
culture requires high cost media and highly skilled personnel for manipulation with 
pathogenic baculovirus, suggesting that this may be the start point for yeast overtaking the 
race with IC-BEV system. In this view, it is worth of mentioning that number of yeast 
species for production of VLPs and other pharmaceuti als has been increasing.  
Currently, beside S. cerevisiae, methylotrophic strains Pichia pastoris  and Hansenula 
polymorpha are well recognized producers while dimorphic Arxula adeninivorans 
represents a novel platform that still has to establi h itself for biomedical applications [157, 
184, 195]. Finally, couple of studies have demonstrated that S. cerevisiae not only 
assembles VLPs but also supports packaging of the recombinant DNA which comprises 
the cognate viral encapsidation elements. This was firstly shown for S. cerevisiae 
assembled Bovine papillomavirus-type 1 particles, able to replicate and package viral ds 
DNA, and thus, form infections virions in yeast cells [196] (see below). In addition, MS2-
phage VLPs were able to package heterologous, HIV-1gag mRNA inside the yeast cell 
[177]. These two examples may resemble extended arms of S. cerevisiae expression 
system applicability toward production of DNA and RNA delivery vectors. 
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1.3.3. Saccharomyces cerevisiae supports replication of different RNA 
and DNA viruses 
Beside its prominent medical importance in the view of vaccine production and public 
protection from two deadly pathogens, S. cerevisiae has been also used in the basic virus 
research for understanding complex biology of numerous pathogenic virusus and clarifying 
the function of the individual proteins from HIV1 or Hepatitc C  [197, 198]. As the cell 
biology and genetics of higher eukaryotes are highly complex, a simpler eukaryotic 
organism, such as bakery yeast, was a good choice fr virus propagation toward 
elucidation of still unknown aspects of viral life cycles. This owes to its highly conserved, 
fundamental biochemical pathways and more than 40% conserved sequences homology 
with known human genes (www.yeastgenome.org)  Besides, commercially available yeast 
gene-deletion library, covering around 85% of all yeast genes (excluding essential ones) 
was a valuable tool for screening host factors thatsupport or inhibit viral replication 
(reviewed in [199]). Furthermore, the natural S. cerevisiae viruses, two viruses with 
ssRNA genomes and two viruses with double stranded RNA genomes [200], were useful 
tool for better understanding of life cycles of RNA viruses in general, and for identifying 
host factors involved in their replication. For instance, one of the common negative 
replication regulators for these viruses and Brome mosaic virus (+RNA) was shown to be 
involved in a degradation of non-polyadenylated mRNAs, thus playing a role in natural 
yeast replicons [199]. 
Until now, many RNA or DNA viruses that infect plants (Bromoviridae, Tombusviridae, 
Geminiviridae and Avsunviroidae familiy), animals (such as the Flock House, Nodamura 
and Bovine Papillomaviruses) or humans (Human Papilloma Virus), are shown to be 
efficiently replicated in yeast (reviewed in [199, 201]) (see table 1.2).  
As presented in the table, both + strand RNA genomes of the three virus groups and closed 
circular (single stranded) RNA of the viroid group (the smallest known pathogenic agents) 
can be replicated in a nonconventional host, Saccharomyces cerevisiae. The first one 
among them to be described was Brome Mosaic Virus (BMV), whose triple, coding 
mRNA genome was efficiently replicated and encapsidate  in the yeast cell. Couple of 
subsequent studies of the underlying mechanism and host players in BMV replication 
revealed many important aspects the life cycle of this virus, such as the process of template 
selection and replication complex assembly in the vesicles of endoplasmic reticulum [202, 
203]. Similarly, studies of Tombusvirus replication revealed that CIRV members of this 
family replicate in association with intracellular membranes of mitochondria [204], 
whereas CNV replicates at peroxisomal membranes. Moreover, cis acting elements of viral 
RNAs, fundamental for replication, were also identified in yeast studies [205]. Finally, the 
only higher eukaryotic RNA virus, able to both replicate and assemble infections virions 
inside of S. cerevisiae cell belongs to the Nodaviridae family of animal viruses.  
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Studies of RNA viruses’ replication in yeast, using traditional yeast mutagenic analysis and 
genome-wide screening approaches upon yeast deletion ibraries, resulted in the ground-
breaking identification of multiple host factors required for viral RNA replication and 
recombination. Moreover, the features of RNA viruses’ r plication in yeast cells, such as 
existence of organelle-like RNA replication factories, were the recapitulation of the ones in 
their corresponding natural hosts, including higher eukaryotic viruses [199, 206, 207].  
So far, two large families of DNA viruses, Papillomaviridae and Geminiviridae (Table 
1.2), with circular dsDNA and ssDNA genomes, respectiv ly, have been described to 
efficiently replicate in S. cerevisiae. 
Table 1.2: Viruses that replicate in yeast 












Brome Mosaic Virus (BMV) [202, 203, 
208] 




Carnation Italian RingspotVirus (CIRV) 
[204, 209] 
Cucumber Necrosis Virus (CNT) [205] 
Tomato Bushy Stunt 
Virus (TBSV) [210] 




Flock House virus [206] 
Nodamura virus [211] 
(+) RNA Animals 
 








s Papillomaviridae Human Papillomavirus (HPV) [213] dsDNA circular Humans 
Bovine Papillomavirus (BPV) [172, 
196] 
dsDNA circular Animals 
Geminiviridae Mung bean yellow mosaic India virus 
[214] 
dsDNA circular Plants 
The first one includes oncogenic Human papillomavirus (HPV) and Bovine papillomavirus 
(BPV). Recombinant genomes of HPV-types 11,16,18 and 31 and BPV-type 1 replicate 
stably as episomes in S. cerevisiae, in the absence of any viral proteins, completely 
depending on the host replication machinery (highly conserved among yeast and humans) 
[213]. The striking finding of another research group was the ability of higher eukaryotic 
Bovine papillomavirus to fully complete its lyfe cycle in the yeast cellular environment, 
starting from infection of the yeast protoplast, over iral replication, particle formation and 
genome packaging into viral shells, thus forming infectious BPV-1 particles [172].  
Further development of new yeast-based replication platforms for large number of 
pathogenic or deadly viruses will help understanding complex virus–host interactions 
providing new targets for antiviral drug development. Moreover, these studies, together 
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with the possibility of creating “humanized yeast systems” by coexpressing human 
proteins essential for viral replications, encourage design of a novel, yeast-based 





2. PROJECT I: Expression of AAV structural and non-
structural proteins and assembly of virus-like particles in 
yeast S. cerevisiae 
2.1. The aim of the project: 
Stable expression of AAV structural proteins in S. cerevisiae cell and optimization of their 
relative molar ratios as a prerequisite for highly ordered interactions of capsid protein 
subunits toward generating icosahedral capsid like structures.  
2.2. The background of the project 
2.2.1. Critical components of AAV2 capsid assembly in the recombinant 
background 
So far, AAV2 capsid assembly has been studied in two, evolutionary far, eukaryotic 
cellular systems – mammalian and insect cell. The common concept accepted in these 
systems is that assembly process does not require the xpression of viral genes other than 
cap gene [53, 215], the general rule of VLP assembly [184]. In order to define minimal 
requirements for production of infective AAV virions, the three capsid proteins have been 
expressed separately and in combination and their assembling capacity investigated in 
different recombinant backgrounds, including in vitro studies of capsid protein 
oligomerization and formation of capsid-like structures [216] and in vivo studies in the two 
aforementioned systems, Spodoptera frugiperda Sf9 insect cells - baculovirus  system 
[215, 217] and mammalian cells (mainly HEK-293 and HeLa cell-lines) (reviewed 
elsewhere, [218]). In these studies the requirement for each capsid protein in the formation 
of intact particles was assessed in the absence of other AAV proteins, adenovirus (Ad) 
helper function and packageable AAV genomes. Althoug  with some contradictions, these 
studies uniformly proposed either VP1 or VP2 to be essential for capsid assembly, 
probably due to their ability to localize major capsid protein, VP3, to the nucleus, the site 
of capsid assembly [53, 217]. The main contradiction n these studies related to the 
sufficiency of VP3 alone in forming capsid shells ([215-217, 219], reviewed in: [48, 49]) 
has been resolved recently with a discovery of a novel AVV2 regulative protein (AAP), 
indispensible for VP3 assembly in virus like particles in the absence of other two VPs [49].  
VP3 constitutes the surface topology of AAV2 capsids, while the largest capsid protein 
VP1 is shown to be essential for viral infectivity. Later, this was explained by the presence 
of N terminally-located phospholipase domain (PLA2) and nuclear localization sequences 
(NLS), thought to be necessary for endosomal escape [56, 62, 220] and nuclear entry [65, 
221, 222], respectively. On the contrary, the other scarce capsid rotein, VP2, is shown to 
be non-essential and can be omitted when 
recombinant background [219, 221]. 
In order to study the permissiveness of yeast 
particle assembly we analyzed the expression of 
natural p40 promoter and from yeast cell-derived
the best expression system that would promote 
The rational for testing AAV promoters in yeast comes from 
showing that a number of wt viral gene control 
cerevisiae [202]. Even more complex elements, such as Hepatitis C virus IRES (internal 
ribosomal entry site), do not require natural
cerevisiae. All proteins necessary for internal initiati
encoded by S. cerevisiae genome [197]  
2.2.2. Regulation of Cap protein expression 
The three AAV2 capsid proteins, VP1, VP2, and VP3, are expressed from two mRNAs, 
differentially spliced from 2.6kb p40 mRNA precurso. Translated from overlapping 
ORFs, these proteins differ only in their N
Different estimations of VP1:VP2:VP3 ratios in AAV2 virus shells have been published so 
far, ranging between1:1:8 and 1:1:20, respectfully (reviewed in 
composition is thought to reflect the stoichiometric atio of the three VPs inside the 
producing cell [51], which in turn is regulated on transcriptional and translational leve . In 
mammalian cells, the two largest AAV non
been shown to regulate expression from the p40 promoter and this regulation is even more 
pronounced in the presence of the helper virus 
 
So far identified cis-acting elements required for 
p5 promoter and ITR located RBEs, p19 CArG
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infective virions are to be produced in the 
S.cerevisiae-in vivo system to AAV2 viral 
AAV capsid proteins both from their 
 promoters, with the purpose of finding 
VP protein self-assembly into AAV VLPs. 
studies of other viruses 
elements retain their functionality in S. 
 (human) trans regulators for its activity in S. 
on of translation from this element are 
in the natural background 
-terminal region as shown in the Figure 2.0.  
[147]). The capsid 
-structural proteins, Rep 78 and Rep 68, have 
[34, 36, 223, 224]. 
Figure 2.0: Cap gene organisation. 
The top part of the picture shows the 
portion of the AAV2 genome on a scale 
of  100 map units (1map unit is approx. 
47 nucleotide) comprising cap gene from 
p40 promoter (map unit 40) till common 
polyA site (map unit 96). Underneath, 2 
cap mRNAs are presented as arrows, 
with indicated intron–exon organization 
and translational start and stop codones 
for proteins encoded by these mRNAs. 
Three structural VP proteins and a non-
structural protein, AAP, are shown 
above corresponding mRNAs, in boxes. 
p40 transactivation by Rep proteins are: 
-like element and p40 proximal Sp1 site 
27 
[34]. However, differential effects of large Rep proteins on all three AAV promoter 
activities in 293, HeLa and other cell lines imply the crucial role of cellular factors in Rep 
mediated p40 transcriptional regulation [36]. These observations have to be taken into 
consideration when AAV-2 capsids are produced in the recombinant background where 
capsid proteins are expressed from Rep-Cap expression plasmids lacking terminal repeats. 
Accordingly, in the novel yeast-cell expression system, we were curious to test the 
potential influence of Rep proteins (Rep78 or Rep68 in particular) on the Cap protein 
expression from the wt p40 promoter, both when Rep proteins were expressed from viral 
p5 and p19 promoter in their natural genomic configuration, and when expressed from a 
heterologous yeast promoter. 
2.3. Results 
2.3.1. Expression of AAV structural and nonstructural proteins from 
natural viral promoters and influence of Rep proteins on capsid protein 
expression in yeast S.cerevisiae 
Protein Expression from wt AAV promoters  
AAV viruses lack the cognate RNA polymerase, depending on the host transcriptional 
machinery for expression of its proteins. Remarkable homology between S. cerevisiae and 
human transcriptional apparatus [225] increases the possibility that AAV promoters could 
be functional in this simple eukaryote. To test this ypothesis we made a yeast-cell 
compatible multi-copy plasmid containing unmodified AAV2 cap gene with all regulative 
elements: p40 promoter, intron element and polyadenylation signal. To do this the entire 
VP expression cassette located between 1428 and 4495 nucleotide position of AAV2 
genome (numbering is as for the sequence under GenBank accession no. AF043303.1) was 
cloned into the yeast episomal YEplac181 (Leu2 gene as a selection marker) The resulting 
plasmid, nominated Yplac p40Cap, has yeast 2-micron origin of replication which 
constantly provide the cell with 20-50 copies of the recombinant gene per haploid yeast 
genome [226] and thus, might compensate for the weak activity of foreign p40 promoter 
and other heterologous control elements. The schematic representation of the Yplac 
p40Cap construct is shown in the  Figure 2.1-A, left part. 
Regulation of VP protein expression by large Rep proteins in mammalian cells is mainly 
achieved through transcriptional regulation of p40 promoter activity and post-
transcriptional maturation of its precursor mRNA [227] (although not as prominent as in 
the presence of adenovirus and ITRs). As mentioned before, the first process is dependent, 
in cis, upon sequences associated with p5 and p19 promoter elements [223], while the 
second one is mostly pronounced when the AAV2 intron element is paired to its natural 
promoter and extended polyadenylation signal [227]. To keep the same regulation network 
in yeast cell, we introduced rep and cap gene (in their wt genomic configuration) into the 
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yeast vector, thus keeping p5-RBRs, p19, p40, intron and AAV2 polyadenylation element 
in the authentic relative positions. The resulting construct, named YplacRepCap (fig.2.1B-





Figure 2.1: Expression of AAV2 Cap and Rep 
proteins from natural promoters in yeast.  
(A-B): Scheme of the plasmid pSub201harboring the 
wt AAV2-genome, used to make two novel plasmids:  
the Yplacp40Cap containing genuine AAV2 cap gene 
(A-right) and the YplacRepCap, containing both the 
wt rep and the cap genes (B-top). Plasmids were 
transformed  in RSY12 cells and Western blot 
analysis of VP protein expression (A-right and B-b) 
was performed using the monoclonal antibody B1 
while for detection of Rep proteins (B-a), the 
monoclonal antibody 303.9 was used. All Rep 
isoforms were detected in insoluble fractions of the
total cell lysates (extract2).  
(C): Western blot-based comparison of VP protein 
expression in the absence (Yplacp40Cap) or presence 
of Rep proteins (YplacRepCap). Extracts from cells 
transformed with YEplac181 (empty vector) were 
used for as –control. Denatured, 293-cell-derived, 
AAV2 capsids were used as + control. Loading 




In yeast, all Rep isoforms are detected when their expression is regulated by viral, p5 
and p19 promoters (YplacRepCap construct) (fig. 2.1.B), while VP3 that is the only 
capsid protein detected from p40 promoter, both in the absence (Yplacp40Cap) or 
presence of Rep proteins (YplacRepCap and Yep-Rep78p40Cap vector) (fig. 2.1-C 
and fig. 2.2-B-b). 
Plasmids Yplacp40Cap and YplacRepCap, and the original vector YEplac181 were 
transformed in the haploid strain RSY12 of S. cerevisiae. This strain has a double 
auxotrophy (Leucine and Uracile), so both URA3 and LEU2 gene markers can be used to 
select for transformant yeast cells. Growth curves of hake-flask cultures of Yplacp40Cap, 
YplacRepCap  and YEplac181control plasmids-transformed cells were similar (data not 
shown), with doubling time of about 2.7 h for exponentially growing cells, when glucose 
was used as the carbon source. During the culture time span, 2x108 cells were collected at 
4 different time points and subjected to protein extraction under denaturizing conditions to 
yield total cell protein extracts. The first two time points correspond to early exponential 
(log) growth phase, the third one to mid-log phase nd the forth one to the late-log/early-
stationary phase. Cap protein expression was analyzed by Western blot analysis of total 
cell lysates at each of these time points (fig. 2.1, parts A and B-b) (“optimized post-
alkaline” extraction method was used and will be described in the next section). Part A 
defines capsid proteins found in Yplacp40Cap-cell lysates, while part B-b shows total cell 
extracts from YplacRepCap-transformants. The only capsid protein expressed from p40 
promoter in both Yplacp40Cap and YplacRepCap transformed cells was VP3. VP3 
accumulated with time, following exponential cell growth and biomass accumulation (the 
maximal amount of protein was extracted from mid an late-exponential growth phases, 
fig.2.1, parts A and B). The monoclonal antibody B1, we used, is widely used for detection 
of native VP proteins [53, 228]. The absence of VP1 and 2 was confirmed in both 
immunoblotting and in immunofluorescence (data non shown), by means of another 
monoclonal antibody, A69 which specifically binds N-terminal epitope common to VP1 
and VP2 [53, 228]. Although the figure 2.1 shows overall VP3 concentration in total cell 
extract of transformed cells, majority of this protein was found in insoluble cell aggregates 
(see later). 
In parallel, Rep protein expression was analyzed in extracts derived from YplacRepCap-
transformed clones, collected in two different time points, mid-log and late-log phase. 
Western blot analysis showed the presence of all 4 Rep polypeptides (detected by the 
monoclonal antibody cl.303.9 which recognizes all four Rep species [53, 228]), 
accumulated to the max level by the late-log phase (fig.2.1 part B-a). Although to a smaller 
extent than VP3, majority of Rep proteins, particularly p5 products, were recovered from 
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insoluble protein compartment (extract2) (see later). Since insoluble fraction is richer in all 
Rep proteins, only Western blot result for this fraction is presented in the fig. 2.1-B-a.  
Fig.2.1 part C shows capsid proteins recovered from t tal cell lysates derived from the 
same number of +Rep( YplacRepCap) and –Rep clones (Yplacp40Cap), collected in the 
same mid-late log phase of both cultures (calculated from O.D600). Apparently, there was 
no significant difference in cap protein expression n these two cell clones, neither 
qualitative (VP3 was the only cap protein detected) nor quantitative (relative VP3 amount 
estimated by the band intensity in the Western blot). This fact demonstrated that there was 
no influence of Rep proteins on VP protein expression from p40 promoter in yeast, when 
both rep and cap genes were present in their natural genomic configuration. 
Cap expression in the presence of constitutively expressed Rep78 
To confirm whether Rep expression does not alter th VP protein expression in yeast cells, 
we also analyzed VP expression pattern when the Rep78 xpression is driven by the 
constitutive yeast promoter pADH1. Rep78 expression cassette was cloned upstream of the 
cap gene in Yplacp40Cap resulting in Yep-Rep78p40Cap pl smid (Fig.2.2.A).  
   
Figure. 2.2 A: Scheme of the plasmid 
Yep-Rep78p40Cap 
pGRep78 construct, harboring the Rep78 
cDNA under yeast promoter pADH1,was 
used to make  plasmid Yep-Rep78p40Cap 
that contains ADH-Rep78 expression 
cassette and p40-regulated cap gene. 
 
 
Figure 2.2 B: Cap expression from p40 promoter in presence of Rep 78, expressed from the 
constitutive ADH1 promoter. 
(a) Yep-Rep78p40Cap plasmid was transformed in RSY12 cells. Western blot analysis of Rep  protein 
expression identified Rep isoforms in the extract2 (insoluble aggregates) of total cell lysate. (b) Western blot 
analysis of VP proteins in extract derived from Yep-Rep78p40Cap transformed cells (in the presence of Rep 
proteins) and from Yplac40Cap clones (in the absence of Rep). Extracts from cells transformed with empty 
vector, YEplac181, were used as negative control. Lading control: Constitutive yeast protein 3PGK. 
Denatured, 293-cells derived AAV2 capsid were used as + control for defining VP molecular weights. 
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As shown in the scheme, Rep78 cassette derives fromp.G.Rep78 expression vector 
(published by Cathomen et al. [229]; the courtesy of Weitzman), and consists of Rep78 
cDNA, flanked by constitutive yeast promoter ADH1 (truncated version) and ADH 
terminator. Western blot analysis of rep proteins i extracts derived from yeast cells 
transformed with Yep-Rep78p40Cap construct showed that not only Rep78 protein is 
expressed, but also p19 promoter works and, therefor , Rep 52 is produced from this 
expression cassette (Fig 2.2, B-a). Since p19 promoter is the inherent part of Rep78 cDNA, 
the presence of Rep52 is consistent with previous demonstration of p19 promoter activity 
from YplacRepCap construct. Western blot results for cap protein expression shown in the 
Figure 2.2, part B-b, demonstrate again that VP3 is the only capsid protein expressed in the 
cells that were constitutively producing Rep78 from the yeast promoter. While expression 
of Rep78 from p5 could not been detected in the end-points of the culture growth, the early 
exponential and the late stationary growth phase, Rep 78 expression from constitutive 
yeast promoter was detected in all phases of the culture growth (data not shown). 
However, as shown in the Figure 2.2, part B–b, Rep proteins in Yep-Rep78p40Cap-
transformed cells did not significantly change cap protein expression form p40 promoter 
with respect to no-Rep VP3 producing cells (Yplacp40Cap transformed).  
Solubility of VP3 capsid protein and of Rep proteins in S. cerevisiae protein extract 
The very first analysis of the Rep protein expression from YplacRepCap  construct showed 
that Rep proteins localized to both soluble and insoluble compartment of the yeast cell 
protein extracts prepared by mechanical-glass bead lysis. In this method, soluble fraction 
was obtained by lysis in the buffer with physiological salt concentrations and a low 
concentration of a non-ionic detergent (0.5% Triton X-100), mostly yielding yeast 
cytoplasmic proteins. Insoluble fraction, including majority of nuclear proteins, intrinsic 
membrane proteins and receptors, were recovered from the sediment obtained by high 
speed centrifugation of the crude lysate, after incubation with high strength buffer (1% 
Sodium Dodecyl Sulfate (SDS) and 1% Deoxycholic Acid (DOC)-sodium salt). As shown 
in the Figure 2.3, Rep52 protein was almost uniformly present in both fractions, while 
small amount of Rep 78 was detected only in the insoluble protein fraction. Such a 
distribution might be the reminiscent of the function-related cellular distribution of Rep 
proteins, typical for mammalian cells [43]. 
 
Figure 2.3: Distribution of AAV2 Rep proteins to 
soluble and insoluble protein fraction obtained by 
glass-bead extraction method. 
Western blot analysis showing differentially distributed 
Rep52 and Rep78 to soluble and insoluble protein 
fraction of extracts derived from YplacRepCap 
transformed yeast cells. Extracts from cells transformed 
with YEplac 181 (empty vector) were used as -control. 
Loading control: Constitutive yeast protein 3PGK. 
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. 
On the contrary, no VP3 protein was found in the soluble fraction of extracts derived from 
either Yplacp40Cap or YplacRepCap transformed cells, while only small amounts of VP3 
was recovered from the pellet upon SDS-DOC solubilisat on (data not shown). However, 
this result was poorly reproducible, which led to adoption of another protein extraction 
method, more efficient in extracting maximum amount of proteins from relatively small 
number of cells. The published “post-alkaline” lysis procedure guarantees such an 
advantage over the standard use of glass-bead extraction [230]. Although improving Cap 
expression analysis, ‘‘post-alkaline’’ lysis did not provide absolute reproducibility of the 
data until further optimized with the second extraction from the sediment obtained after 
purification of the total lysate obtained by this method. This sediment contained protein 
aggregates and proteins associated with the cellular membranes, which required harsher 
conditions to be liberated from the cellular structures and efficiently transferred to 
solubilised state. We achieved this by combining solubilising properties of various ionic 
and non-ionic detergents in elevated concentrations, further assisted by sonication. Only 
with this second round of extraction VP3 protein was recovered with 100% reproducibility. 
The obtained fraction of cellular proteins was designated as extract 2 in the presented 
figures. This was deduced from Western blot analysis in Figure 2.4-a, which showed that 
majority of VP3 proteins localized to  extract 2, while only small amounts of this protein 
were recovered in the first round of extraction (extract1), which follows the procedure of 
Kushnirov [230]. This result strongly demonstrates hat VP3 accumulated in insoluble 
aggregates within S. cerevisiae cells, in concordance with results from Sf9 and HeLa cells 
[215, 216]. Together these three evolutionary distant, eukaryotic expression systems 
strongly support an intrinsic propensity of AAV capsid proteins to associate with cellular 
structures. Moreover, with optimization of “post-alk line” procedure (addition of the 
second extraction cycle) we were able to extract all AAV2 proteins expressed in RSY12 




Figure 2.4: Recovery of AAV2 proteins by ”Optimized post-alkaline” extraction. 
a) Western blot analysis of cap proteins in total celextracts obtained by optimized post-alkaline extraction 
method from Yplacp40Cap and YplacRepCap-transformed cells, r vealed majority of VP3 proteins in the 
extract2 (insoluble aggregates). Extracts from YEplac181 transformed cells were used as -control. Denatured, 
293 cell-derived, AAV2 capsids used as + control. L ading control: Constitutive yeast protein 3PGK;  
b) YplacRepCap cells differentially grown to mid or late-log phase (b-right) and YepRep78p40Cap cells grown 
to late-log phase (b-left) were subjected to ”Optimized post-alkaline” protein extraction for Western blot 
analysis of the Rep protein distribution to two proteic fractions obtained by this method. 
Figure 2.4-b shows Western blot result for distribution of Rep proteins to extracts 1&2 of 
total cell lysates derived from YplacRepCap (fig 2.4-b, left) and YepRep78p40Cap (fig 
2.4-b, right) transformed clones. Uniformly for both clones, majority of large Rep proteins 
localized to the extract 2, while small Rep isoforms were almost equally distributed to both 
extracts. Low amounts of Rep68 and Rep 40 were detected only after optimization of the 
extraction method, while they could not be detected with glass-bead-based protein 
extraction. Although poorly expressed comparing to their non-spliced relatives, the 
presence of Rep68 and Rep40 suggests that, albeit weakly, the major AAV intron 
(bounded by eukaryotic-cell conventional donor and cceptor splice sites) is recognized by 
yeast splicing machinery. Poor splicing of foreign intron elements (e.g. in Drosophila 
gene) has already been documented for the S. cerevisiae xpression system [231]. 
In some cases (e.g.ADE8 promoter of Drosophila) foreign promoters are found to give 
aberrant transcriptional initiation in S. cerevisiae [232]. To prove the existence of correctly 
initiated p40mRNAs in YplacP40Cap–transformed yeast cells, we performed PCR 
amplification of retro-transcribed mRNA pool derived from this clone, using specifically 
designed primer pairs. The upstream primer starts wi h p40 transcriptional start site 
(nucleotide position 1853) and is identical to the first 20 nucleotide sequence of 5’ 
untranslated region (5’UTR-Exon1), common to all three putative, correctly initiated forms 
of p40 RNAs: the non-spliced precursor and two differentially spliced p40mRNA species. 
The downstream primer is complementary to 18bp region common to all three VP ORFs 
with the nucleotide position 2758. PCR conditions were optimized in a manner to provide 
the highest specificity of the assay, excluding nonspecific binding to other regions of Cap 
ORF, while non-specific pairing with yeast mRNAs (cDNAs), if any, could be disregarded 
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by comparison with the control PCR (mRNA pool derivd from cells transformed with 
YEplac181-empty vector). In principal, such primer design could distinguish between all 
three putative mRNAs, corresponding to three PCR products of different lengths,  923, 575 
and 549 bp long. PCR products are separated and analyzed upon acrylamide gel 
electrophoresis. However, the only p40 product detect d under most stringent PCR 
conditions was 2.6 kb precursor mRNA (988bp band) (fig.2.5), while other shorter species 




Figure 2.5: Reverse Transcription (RT)-PCR-
based analysis of p40mRNAs. 
Total cellular RNA was extracted from Yplacp40Cap 
and YEplac181 (-contr.) transformed clones, and 
corresponding mRNA pools were retro-transcribed and 
subjected to primer specific PCR under 3 different 
conditions: PCR1 of the lowest stringency and PCR3 of 
the highest one. The PCR products are separated by 
acrylamide gel electrophoresis and stained with EtBr.- 
DNA Marker used: 50bp-1000 bp ladder. 
 
This result, although not obtained with a very sophisticated analysis, suggests that VP3 
protein derives from the 2.6 kb p40-precursor in yeast cells, rather than from its spliced 
product. If so, its expression could be interpreted in the context of the “scanning translation 
initiation” model in eukaryotes. According to this model 40S ribosomal subunits scan from 
the 5' end of an mRNA until reaching an AUG codon suitable for initiation. In these terms, 
the environment of VP1 initiator (GNNAUGG) (as well as of other AUGs present in 
5’UTR) might be suboptimal in yeast cell, alike uncommon VP2 ACG, causing ribosomes 
to bypass till reaching the VP3 AUG resided in the favorable “Kozak-like” context. 
However, 2.6kb-p40 precursor is shown to be very poor template of VP protein expression, 
both in in vitro and in vivo experiments in HeLa cells, probably due to multiple short ORFs 
present in 5’UTR [233]. Taking this into account, we cannot exclude the possibility that 
even a low amount of spliced p40 mRNAs (too low to be detected by RT-PCR-based 
analysis), may still be the main source of VP3 protein in yeast.   
Nevertheless, we did not investigate deeper into the RNA profile of AAV2 proteins 
expressed in yeast cells, but rather focused on finding other strategies for expression of the 




2.3.2. Inducible Yeast Promoter for Regulation of A V2 Structural 
Protein Expression 
Since VP2 was shown to be non essential for infectivity of the AAV2 virions [219, 221], 
simultaneous expression of VP1 and VP3 in yeast cells would be the primary condition for 
developing yeast-cell based system for production of the AAV2-like particles with 
biological properties of the wt capsids.  
Potential reasons for missing VP1 protein expression fr m p40 AAV promoter are 
numerous; low activity of the foreign viral promoter, absence of splicing, inefficient 
transport of non-spliced mRNA to the cytoplasm and/or poor stability of this transcript, 
inefficient translation from non-spliced mRNAs, increased proteolytic degradation of this 
protein in yeast cellular environment etc. The use of yeast promoters and terminators 
should circumvent at least some of these challenges. On the way to creating efficient VP-
protein expression system, we created various construct  based on strong galactose 
inducible promoter pGal1. To this purpose, we used commercially available multi-copy 
vector pYes2, whose multiple cloning site (MCS) is flanked by efficient yeast gene 
expression regulators, Gal1 promoter and cyc terminator. This vector harbors URA3 gene 
for constant selection in auxotrophic RSY12 strain. Figure 2.6-A shows a panel of pYes2-
based constructs in the top-to-bottom order in which each one will be described further in 
the text.  
pYes2-Gal1 promoter-based constructs 
Initially, we tested weather all AAV2 capsid proteins from overlapping ORFs could be 
produced simultaneously when their transcription was regulated by yeast Gal1 promoter 
instead of viral p40 promoter. Cap gene sequence downstream of p40, including intron 
element (the sequence between map pos.1882 and 4495 of AAV2 genome in GenBank, 
accession no. AF043303.1) was introduced in MCS of pYes2 vector and the novel vector 
was designated pYesIntronCap. With this strategy, we wanted to avoid the separation of 
VP ORFs in three different cDNAs, since the VPs expr ssed in this manner did not 
assemble well in tissue culture cells [216]. Beside, elements present in the AAV2 intron 
region (possibly RNAs) contribute to VP protein expression when induced from the CMV 
promoter (Kleinschmidt J., personal communication). The possible analogy with human 
cells was the rationale for keeping AAV2 intron sequ nce between Gal1 promoter and VP1 
start site. RSY12 cells transformed with pYesIntronCap and pYes2 empty vector (as 
negative control) were actively grown on glucose for one or two days before the induction 
of Cap gene expression was triggered upon carbon source exchange in the growth medium 
from glucose to galactose. At the end of glucose growth, a small fraction of actively 
growing cells (108) was collected and lysed for protein extraction, while the rest of the 
culture was subjected to 4h and 8h induction and then processed for Western blot analysis 







Figure 2.6: Expression of AAV2 structural proteins from the galactose
(A): Panel of pYest2 vector-based constructs, arrying differences in
transform RSY12 cells. (B): Western blot analysis of VP protein expression
glucose, transformed clones were exposed to galactose for different induction times. pY
VP3 was detected in the extract 2 of glucose grown cells
grown cells, while no Vp3 was detected after 8h of Gal induction 
in extract 2 after 3h and 5h of galactose-induction 
induction (b-bottom). Extracts from cells transformed with empty vector, pYes2, were used 
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-inducible promoter pGal1 
 cap transcription units were used to 
. After pre-induction growth in 
esIntronCap expressed 
 and to a smaller extent in the extract 2 of 4h Gal-
(a). pYesVP1 K.M-expressed VP1 was found 
(b-top), and in both, extracts 1 and 2, after 7h and  9h 
as -control.  
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During the glucose growth, Gal1 promoter activity is on the basal level which can differ 
from one yeast strain to another (“leaky” or non repressed promoter phenotype is strain-
dependent) [234]. Surprisingly, the only protein expressed from this construct was again 
VP3 and its max amount was detected in the extracts of the cells grown on glucose. After 
the carbon source switch to galactose, some background VP3 level was still observed after 
4h of galactose growth and completely vanished after 8h of induction (fig.2.6B-a). VP3 
was detected only in the extract2. Decrease instead of expected increase in protein level 
after glucose-galactose nutrient switch could not be explained in terms of toxicity of 
overexpressed capsid proteins since no toxicity-related phenotype (e.g. decreased growth 
rate or abolished growth) was observed for gal-grown cells. Instead, galactose metabolism 
seemed to be detrimental for VP protein expression. We proposed one explanation for the 
observed “galactose effect”, based on the hypothesis that VP3 protein is expressed from 
the spliced Gal1 mRNA form. In yeast cells, big environmental changes, sensed as 
stressful, can cause smaller or bigger alterations in splice factors availability and once cells 
adapt to new conditions different splicing pattern is fixed [235]. Carbon source exchange 
with water-wash step in between (temporary starvation) s stressful for the yeast cell and 
even a small alterations in a pool of splice factors could abolish already poor splicing of 
the foreign AVV2 intron. 
To test this hypothesis, we created another vector, named pYesCap, in which the CAP 
coding region without the upstream intron element (the sequence between VP1 ATG, the 
nucleotide pos.- 2203, and common VP Stop codon, pos.- 4410 in the wt AAV2 genome 
sequence), was cloned downstream to the  Gal1 promoter. In the absence of splicing, the 
main protein product expected to be synthesized upon induction, is VP1. However, if VP3 
were produced from non-spliced mRNA, then also the pY sCap plasmid could give rise to 
some VP3 protein level. Instead, neither VP1, nor VP3 was detected from this vector 
regardless the carbon source used (data not shown). The absence of VP3 expression in 
glucose grown cells supports the hypothesis that intron element (the spliced pGal1 mRNA) 
was essential for VP3 protein expression from pYesIntronCap construct. Yet, the absence 
of VP1 synthesis after Galactose induction could have been explained only after we 
introduced following modifications in the VP1 cDNA: 
1. Introduction of yeast Kozak-like element right upstream of VP1 start-site (yeast 
translation initiation consensus sequence designed according to pYes2-vector 
manual, Invitrogen), 
2. Elimination of  an out-of-frame ATG, located between VP1 and VP2 initiation 
codons, 
3. Removal of the major AAV2 splice acceptor (position 2227), downstream of VP1 
ATG   
Although not as efficient as consensus Kozak sequence in mammalian cells, the yeast-cell 
homologous element is thought to provide up to 3 fold increase of translation initiation 
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[226, 236, 237]. The second two modifications are already shown to contribute to 
improved VP expression in Baculovirus-Insect cell system [138]. Elimination of the 
neighboring out-of -frame ATG is supposed to prevent interference with the choice of the 
right ORF, while removal of the splice acceptor should prevent aberrant splicing of VP1 
mRNA. The resulting vector harboring these modifications was named pYesVP1K.M. 
Western blot analysis of the total protein extracts derived from RSY12 cells transformed 
with this vector (obtained by “optimized post-alkaline” extraction method) showed that no 
cap protein was expressed after 12-15 h growth on glucose (data not shown), while 
galactose induction caused gradual increase in VP1 protein expression with max level 
achieved around 7-8h after induction (fig. 2.6B-b bottom). VP1 was the only capsid 
protein expressed in these cells. In the first 5 hours of induction (fig.2.6B-b top) no VP1 
protein was detected in the extract 1 (not shown), hereas a minor portion of VP1 could be 
found n this fraction only after protein accumulation with longer induction times (7h and 
9h in fig.6B-bottom). Just like VP3, majority of VP1 protein was recovered in the extract 2 
(insoluble fraction) of the total cell-lysate.  
 
2.3.3. Simultaneous expression of AAV2 capsid proteins and modulation 
of their stoichiometry toward successful capsid assembly. 
In order to determine assembling abilities of VP1 and VP3 proteins in RSY12 strain 
background, yeast cells were subjected to co-transformation with two plasmid 
combinations (table 2.1): 
1. In the first experimental setting yeast cells were cotransformed with pYesVP1.KM 
and YplacRepCap and selected double-transformants were named “+Rep - double”  
2. In the second setting cells were cotransformed with pYesVP1.KM and 
Yplacp40Cap; these transformants had the same genetic material for capsid protein 
expression as “+Rep-double”, but were lacking in rep g ne, thus named “-Rep -
double” 
Table 2.1: Constructs used to cotransform RSY12 cells for 
simultaneous expression of VP1 &VP3 protein 
Pairs of plasmids 
Labelling of double- 
transformed clones 
pYesVP1 K.M + Yeplac-p40Cap  “ - Rep” double 
pYesVP1 K.M + Yeplac-RepCap  “ + Rep” double 
pYes2 + Yeplac181 - empty vector – control 
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Based on the findings with single transformed clones, the expected expression profile for 
the double transformants would be as follows: 
Continuous expression of VP3 protein and Rep proteins during the whole culture (glucose 
+ galactose), and boost of the VP1 expression afterthe switch from glucose to galactose-
based growth. Yet, Western blot analysis of total-cell lysates derived from “+Rep” and “-
Rep- double” clones, grown for 12h in glucose medium (non-inductive growth phase) + 8h 
in galactose medium (induction phase), showed one discrepancy from the expected VP1-
VP3 expression pattern: As expected, only VP3 protein was produced by actively dividing 
glucose-cultures (both, “+Rep” and “-Rep”- double) (fig.2.7-A); however, after 8h of 
induction in galactose, induced VP1 synthesis was followed by an unexpected decrease in 
the relative amount of VP3 protein – it was hardly etectable in the cell lysate of the 
“+Rep-double” clone, while no VP3 was detected in the “-Rep-double” cell lysate, fig.2.7-
A (the complete VP3 absence observed for “-Rep-double” clone was probably due to 
inferior amount of proteins loaded, as seen from the signal of the loading control 3PGK).  
 
 
Figure 2.7 A, B: VP1 & VP3 expression in double-transformed yeast cells, listed in Table 2.1.  
After 12h growth on glucose, “+Rep” and “-Rep” double c lls were transferred to induction growth on 
galactose. (A) Cells were collected for protein extraction at the end of the glucose culture and after 8h of 
galactose induction and VP protein expression was analyzed by Western blot  (B) Rep protein expression 
before and after galactose growth in “+Rep”double clones was analyzed by Western blot. Extracts from cells
transformed with empty vectors, yEplac181 and pYes, were used as negative control.  
However, Western blot analysis of Rep protein in “+Rep-double” clones showed that both 
p5 and p19 Rep isoforms were “constitutively” expressed throughout the whole culture 
regardless the carbon source used for the growth (fig.2.7-B) and their distribution to 
protein fractions was the same as seen before for the cells transformed with YplacRepCap; 
Rep78 was recovered in the extract 2 (insoluble fraction), while Rep52 was detected in 
both extracts; small amount of Rep68 and 40 were found only in the second extract. 
Probably the most interesting observation from thisanalysis was the loss of Rep68 during 
galactose growth, which may support the general hypothesis that splicing was negatively 
affected by the carbon source switch. A minor decrease in the Rep78 and 52 level after 
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galactose growth was probably the result of decreased growth rate in this carbon source 
(doubling time in galactose is almost twice as much the one in glucose, 4.5 h vs 2.7 h). 
Decrease in VP3 protein level during culture growth on galactose suggests that 
galactose catabolism either prevented e novo synthesis of this protein or decreased 
its expression rate, resulting in VP3 “dilution” in the growing cell population. 
Taken this into account, induction phase on galactose was gradually decreased and the 
situation improved. Figure 2.8 shows relative amounts of VP1 and VP3 proteins at 
different time points of galactose-grown “+Rep-double” yeast cell clones. Time “0h” 
corresponds to the end of the pre-induction growth phase, in 2% glucose medium, when 
only VP3 protein was accumulated. After glucose growth, cells were pelleted, water 
washed and transferred to 5% galactose medium. At different time points of galactose-
induction (indicated in the figure) cells were collected for “optimized” cell protein 
extraction procedure, yielding two protein fractions, united prior to gel electrophoresis and 
Western blot analysis, for more correct analysis of VP1:VP3 ratios at each time point. VP1 
expression was observed already 40 min after galactose induction (fig. 2.8, part-a, right) 
and its fast increase in the first 3h was followed with little or no reduction of VP3 protein 
in this time frame, observed by comparison of VP3 band intensities (fig. 2.8-a, left). With 
the induction time extended over 3 hours, a gradual increase in VP1 expression was 
followed by a decrease in the VP3 level, which was no longer observed at the end of 
galactose culture (8h), when VP1 expression reached its maximum (fig. 2.8-a, left). 
pYesVP1.KM + Yplacp40Cap double-transformants (“- Rep - double” clone) showed 
similar VP1:VP3 expression pattern over the time span of glucose + galactose growth (data 
not shown). The gradual increase of the relative VP1: 3 ratio was calculated from 
corresponding band intensities at each of the indicated times and the values are presented 
in tabular format (fig. 2.8-b). This ratio most closely resembled the wt VP stoichiometry 
when galactose induction was reduced to 40 minutes from the moment when VP1 protein 
was first detected. The importance of the “correct” stoichiometry of capsid protein subunits 
has been already discussed and well reported to influence external capsid topology and 
thus, infectivity of produced particles, rather than efficiency of assembly per se [219]. 
Nevertheless, the weak point of the “short induction” strategy,  in terms of VP1:VP3 
optimization, is the difficulty in determining the exact time point at which VP1 expression 
homogenously set in for all cells in the population. This was observed by incomplete 
experimental reproducibility when the same growth conditions were repeatedly applied. In 
some cases cells responded to the same, “optimal” induction time (40min.) with either 
superior level of VP1 expression (comparing to the on  shown in fig. 2.8-a) or with no 
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Figure 2.8: The “short induction” strategy 
After 17-24h growth on glucose, “+Rep”-double cells were transferred to induction growth on galactose. Cells 
were collected for protein extraction and Western blot analysis of VP1 and VP3 expression at the end of the 
glucose culture (“0” time point) and at various time points of galactose
at each time point were determined by band densitometry and obtained values are shown in the Table. Th best 
ratio, 1:9=0.11, was obtained after 40 min of galactose induction 
Induction time up to 2-3h falls within the 
divisions), typical of glucose-galactose nutrient 
consumption yeast gal-genes are repressed 
Likewise, repression of recombinant Gal promo
relieved shortly after glucose depletion a d small altera
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for shake-flask cultures), could cause either 
regulated promoters. Moreover, water wash
which, some cells in the population are temporarily 
can further increase variations in cell responses to substrate tr nsition
working with cultures at “transition state” becomes difficult and unsustainable
water wash-step between medium exchanges 
system. 
To avoid these challenges, we tried the
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concentrations of glucose and galactose in “inductive” medium 
time. We tested this approach under two different nutrient conditions: 
(1.5%) and high galactose (2.5%) and 2.  low glucose 
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Figure 2.9 A: “High glu-high gal” - 
Western blot analysis of VP1:VP3 expression. (A): Glucose
“induced” in presence of high glucose (1.5%) and high galactose (2.5%). “0” time poi
preinductive, glucose growth phase, and the beginning of the mixed
9h or 18h of induction. The best VP1:VP3 ratio was detected for 9h induction time.
This increase in Vp3 level is consistent 
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was detected 9h after the beginning of the culture 
point was quite optimal (around 1:9). Although insignificant for the “correct” VP1:VP3 
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VP1 expression under high glu-high gal growth conditions
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galactose utilization [238], suggesting more uniform “transition state” and thus
uniform onset of VP1 accumulation for  cells in the population.
Finally, based on these r sults we hypothesized that by 
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Table: The gradual increase of
ratio with extended induction time
 Induction 
time 4.5h 5.5h
 VP1/VP3 0.13 0.23
 
 
Figure 2.9 B: “Low glu-high gal” - strategy for optimization of VP1:VP3 ratio:
Western blot analysis of VP1:VP3 expression (B-top)
low glucose (0.5%) and high galactose (5%) and  cells were lysed before induction(“0h”) and after  5 different 
periods of induction. (B-bottom): the VP1:VP3 ratios are presented in the Table. The best ratio
detected after 4.5h induction.  
The best VP1:VP3 ratio was obtained for 4.5h induction period, which according to band 
intensities was approx. 1: 8. In this time frame, initial grow
concentration enabled the cell culture to divide after approximately 3h from the “mixed 
culture” onset while preserving de novo VP3 synthesis. The 1
delayed 2nd division – aprox. 8h after the culture onset, 
glucose to galactose metabolism (doubling time on galactose is 5h). Thus, the gradual 
increase of relative VP1:VP3 ratio, calculated from band intensities and schematically 
presented in the table (Fig.2.9, B-bottom), probabl
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to 2nd cell division. After the 2nd division, VP3 dilution in the cell population in the absence 
of its de novo synthesis contributed to more prominent VP1:VP3 increase.  
On the whole, the benefit of “low glu-high gal” over “high glu-high gal” strategy was 
obtaining preferential VP1-VP3 expression pattern in two times shorter period (4.5h 
instead of 9h). 4.5h induction on 0.5% glucose + 5% galactose was considered as “optimal 
induction”. Together, 12h preinductive-logarithmic glucose growth plus 4.5h of the 
inductive growth were considered as “optimal growth conditions” under which the 
favoured VP1:VP3 ratio was achieved by: continuous VP3 accumulation, from the 
beginning of the glucose culture till the end of the mixed culture, while VP1 protein was 
produced during the inductive phase of the mixed culture.  
2.3.4. Assembly of yeast-cell derived recombinant capsid proteins  
High-speed ultracentrifugation through 40% sucrose-cushion. 
To test the permittivity of yeast-cellular environment for VP1 and VP3 assembling in 
icosahedral virus-like particles, “+Rep-double” and “-Rep-double” clones were grown 
under “optimal” conditions. 3g of yeast cell biomass (~400 x 108) of each clone was lysed 
and processed by the method compatible with VLP extraction (under non-denaturing 
conditions), while a small aliquot of induced cells ( 1 x 108) was processed by optimized 
post-alcaline extraction method for Western blot analysis of relative intracellular levels of 
VPs in the total-cell lysates. 
As seen before, individually expressed capsid proteins accumulated mainly as part of 
insoluble aggregates in total-cell lysates and were r covered after couple of sonication 
cycles in buffer with high concentrations of ionic and  anionic detergents which 
consequently denatured the proteins. To enhance prot in solubilisation, without damaging 
VLP structure, we used mild non-ionic detergents (DOC and NP-40) and elevated salt 
concentrations (0.5M NaCl) in the extraction buffer (DNS buffer). Large yeast biomass 
was disrupted by glass beads homogenization (see chapter 4). Besides, all so far used, 
AAV2 production systems, in vitro, Sf9 insect and HEK293 cells, showed that VP 
assembly intermediates and virus particles achieve b tter solubilisation in buffers of high-
ionic strength [240]. Yeast cells were lysed by extended glass beads homogenization + 
short sonication in DNS buffer. In order to enrich putative virus-like structures in the 
soluble fraction, 15.000 g-centrifugation sediment of he crude lysate was subjected to the 
second extraction with elevated number of sonication cycles. United extracts were cleared 
from cell debris and subjected to ultracentrifugation through 40% sucrose cushion. 
Resulting pellet and supernatant fractions were analyzed by Western blot analysis for VP 
protein composition (fig. 2.10, A). VP proteins were found in the ultracentrifuge pellet and 






Figure. 2.10: Concentrating VP assembly products by high-speed ultracentrifugation through 
40% sucrose-cushion. 
(A): “+Rep “ double yeast cells induced for 4.5h in 0.5 % Glu + 5 % Gal  medium were subjected to a small 
scale-protein extraction (under denaturing  conditions) and to a large scale, non-denaturing extraction. After 3h 
ultracentrifugation in 40% sucrose cushion of the native extract, supernatant and pellet fraction of the native 
protein extract were analyzed by Western blot for the presence of VP proteins. VP1, 2 and 3 were detected only 
in the pellet fraction, in the relative ratio ~1:2:6. VP1 and VP3 recovered in the total cell lysates w re in the 
relative ratio 1:8. (B): YplacRepCap-transformed, pYes-VP1 KM- transformed ancells cotransformed with 
both plasmids (“+Rep double”) were induced for 6.5 h in 0.5 % Glu + 5 % Gal medium. Small and large scale-
protein extracts were processed as described in (A). Relative frequencies (numbers in red) of VP1, VP2 and
VP3 in the ultracentrifugation pellets were analyzed and compared with relative amounts of VP proteins in the 
corresponding total cell lysates.  
Surprisingly, beside VP1 and VP3, Western blot analysis of the pelleted material for the 
first time revealed the presence ofVP2 protein. This result was interpreted in terms of low 
overall VP2 expression, whose concentration in the bulk of yeast proteins (in the total cell-
lysate) was under detection limit of Western blot analysis. Nevertheless, putative localized 
distribution of capsid proteins inside the yeast cell could increase “local” VP 
concentrations, allowing inter-VP homo and/or hetero oligomerization. Moreover, after 
4.5h induction, VP1: VP3 ratio, detected in the ultrac. pellet (aprox.1:6, according to band 
intensities) was similar to the one in the total cel lysate (aprox.1:8). Though, VP2 was 
almost as frequent as VP1. 
To confirm that the ratio of VPs in the pellet resembled their relative intracellular levels, 
cells were grown under “suboptimal” conditions that were shown to result in VP1: VP3 
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ratio higher from the “optimal” one. For instance, lls were induced for 6.5 h in 0.5% glu 
+ 5% gal medium, previously shown to result in VP1:VP3 ratio 1 : 3.3 (see fig. 2.9, B-
bottom). In addition, in the same experiment, we investigated the origin of VP2 protein 
expression since both constructs used for VP1 and VP3 expression comprised unmodified 
VP2 ORF. To do this, yeast cells transformed with single plasmids, VP1 expressing 
construct (pYesVP1K.M) and Vp3 expressing construct (YplacRepCap), were grown 
under the same conditions as double-transformed yeast cells (+Rep double), with 6.5h 
induction period. After induction, all three cultures were processed for “capsid 
purification” and subjected to 40% sucrose cushion ultracentrifugation. In parallel with the 
ultracentrifugation pellet analysis (fig.2.10, B-right), the total cell-extracts of single-
transformed cells (processed by “optimized post-alkaline” extraction) were analyzed by 
Western blot to monitor the relative intracellular levels of VPs (fig.2.10, B-left). 
This analysis yielded the following results: 
1. In the ultracentrifugation pellet derived from pYes2VP1K.M – transformed cells, 
all three VP proteins were detected (fig. 2.10, B-right). As expected, the amount of VP2 
in this pellet was inferior to VP1, but the level of VP3 protein was higher than expected 
from read-through translation mechanism (the relative VP1:VP2:VP3 ratio in this pellet 
was 1: 0.25: 0.9). Besides, as seen before, the absence of VP2 and VP3 from the total cell 
protein extracts (fig.2.10-B-left) confirmed their low overall intracellular concentration in 
the bulk of yeast proteins. However, oligomerizing /assembling properties of capsid 
proteins enabled the visualization of the two scarce VPs after assembly products were 
concentrated by ultracentrifugation;  
2. The only capsid protein uniformly found in the ultracentrifugation pellet derived 
from YplacRepCap transformed cells (fig.2.10-B-right) and in the corresponding total 
protein extract (fig.2.10-B-left) was VP3. The presence of VP3 in the pellet suggests that 
this protein alone is able to form super-molecular-weight oligomers or higher order-
structures, concentrated by high-speed ultracentrifugation through 40% sucrose cushion;  
3. After 6.5 h induction, the relative VP1:VP3 ratio in the ultracentrifugation pellet 
derived from double-transformed yeast cells (“+Rep”-double) was almost identical to 
their intracellular stoichiometry.  In detail, under suboptimal growth conditions (6.5h in 
induction) the relative VP1:VP3 level in the total cell lysate (deduced from band 
densitometry) was 1:3 (fig.2.10-B-left), while the VP1:VP2:VP3 ratio in the corresponding 
ultracentrifugation pellet was 1: 0.5: 3.3, respectiv ly (fig.2.10-B-right). 
Putting together the results obtained for +Rep double clones after 4.5h and 6.5h induction 
(characterized by great excess of VP3), we can bring out the conclusion that capsid 
assembly intermediates consisted of VP1 and VP3 in the relative ratio similar to their 
relative intracellular levels. However, upon high-speed ultracentrifugation VP2 was almost 
as efficiently recovered as VP1 protein, although its intracellular concentration was lower 
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and thus, undetectable by Western blot. Moreover, w detected almost the same amount of 
VP1 and VP3 in the pellet derived from pYesVP1KM-transformed cells, which is in the 
contradiction with the overall concentration of the t ree capsid proteins in this cell clone. 
In addition, we can say that VP3 alone was able to form super-molecular weight structures, 
suggesting that the main AAV2 capsid constituent, VP3, could be the limiting factor in 
highly-ordered interactions of cap proteins in yeast cellular background. Another factor 
that may be important for shaping VP protein interactions and assembly properties is the 
local concentration of the three VPs in cellular compartments permissive to VP 
assembling. 
Fractionation of assembled capsid proteins by ultracentrifugation in CsCl gradient  
To further characterize types of assembly-products concentrated by 40% sucrose cushion 
ultracentrifugation, a bigger culture volume of “+Rep-double” cells was grown under 
“optimal” conditions and 10g of yeast biomass were processed for “capsid purification” by 
glass-bead homogenization and subjected to 40% sucrose- ushion ultracentrifugation. 
Assembly products concentrated in the pellet were rsuspended in DN buffer and DNAse 
digested to improve solubilisation. After clearance of aggregated, “junk” material, 6 ml of 
the supernatant (“CsCl input”) was subjected to fractionation by CsCl density gradient 
centrifugation. 0.5% of the total input volume was nalyzed in Western to determine 
relative amounts of capsid proteins in the “input” material (fig. 2.11-A). In the same figure, 
capsid proteins detected in the “junk fraction” represent the fraction of assembly products 
which failed to solubilise and were lost as aggregat d material. These proteins were 
disaggregated only after resuspension in standard protein loading buffer followed by high-
temperature incubation.  Two different volumes of denatured “junk” fraction were 
analyzed for better estimation of the relative amount of lost material, suggesting that 
approximately 5-10% of the total VP protein yield recovered by the first 
ultracentrifugation was lost due to poor solubilisation.  
After 48h of CsCl fractionation, 13 different fractions of gradually increasing densities (f1 
is the fraction of the minimal density (1.370) and f13 of the maximal one (1.475)) were 
collected, dialyzed against PBS, and each fraction was analyzed for VP protein 
composition in the Western blot (fig.2.11-B). Small iquots of two or three adjacent 
fractions of similar density (1+2, 3+4, 5+6+7, 8+9, and 10+11) were united for 
transmission-electron microscopy (TEM)-based detection of putative capsid-like structures 
(fig.2.11-C). Fraction 13 (named “pellet”) was not analyzed. 
Western blot identification of VP-containing fractions 
For the highest assay sensitivity, maximal volume of each fraction was loaded on SDS-
page gel and blots were incubated with both B1 and A69 Ab (with partial stripping step in 
between-see chapter 4) (fig.2.11-B). The analysis revealed all three capsid proteins over 
the range of fractions, in different combination. I the 1st fraction (one of the lowest 
density), only VP3 protein was detected, probably resembling VP3 homo
smallest molecular weight; fractions 2 and 3 contained almost equal amounts of VP2 and 
VP3; the 4th fraction contained all three VP proteins
fractions; finally, 8-11 fractions contained all three VPs. Relative VP frequencies (1:2:7) in 
f8-f11 most closely mirrored and the ones found in 293
(1:1.5:8) used as positive control (a kind gift from Mauro Giacca’s lab
capsid protein detected in f12. Very weak band intensi y in each fraction
last fraction- f13 (“pellet”), suggested that lot of in
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Figure.2.11. Purification of yeast cell-derived AAV2 capsid like-structures by CsCl-gradient 
ultracentrifugation. 
Native protein extracts derived from “+Rep” double yeast cells induced for 4.5h in 0.5 % Glu + 5 % Gal 
were subjected to 40% sucrose cushion-ultracentrifugation. Pelleted material was resuspended in capsid-
resuspension buffer (see chapter 4) and cleared from insoluble aggregates = “junk” by high-speed 
centrifugation.  
(A): Western blot analysis, using mAb B1, shows relative frequencies (numbers in red) of VP proteins in 
0.5% (30µl) of the native extract, “Input”, and relative amounts of VP proteins lost as insoluble aggre ates 
in “Junk” fraction.  
(B): The Input was subjected  to  CsCl –gradient ultracentrifugation for 48 h. 13 fractions of different 
densities  were  recovered and analyzed  for the presence of VP proteins by Western blot. Structures 
recovered in fractions 8-11 had VP compositions that most closely resembled the one of wt capsids.  
(C): Fractions of similar densities (indicated in the same colour) were united and subjected to TEM 
analysis. Capsid-like structures of ~20nm size were identified in fraction f8+f9 (i) and compared with 
293T –derived AAV2 empty capsids (ii ). Scale bar is 40 nm. 
(D): 3 fraction pairs that gave positive results in TEM were spotted on the nitrocellulose membrane in 
three quantities indicated on the right side bar and alyzed for the presence of AAV capsids with the 
capsid-specific mAb A20 antibody. The strongest signal (which indicates the greatest number of capsids) 
was detected in the fraction f8+f9. As negative control of the assay, the same number of cells 
cotransformed with empty vectors, Yplac181 and pYes, were processed as described in (A) and the 
obtained CsCl fractions of the corresponding densities w re incubated with A20. 
Electron microscopy analysis of CsCl fractions 
After fractions of similar densities were united, four resulting “fractions” were analyzed by 
negative staining and electron microscopy. Groups of capsid-like structures were observed 
in 2 out of four fractions, f8+f9 (fig. 2.11-C) and f10+f11 fraction, while in the fraction 
f3+f4 only singular globular structures, of the correct size (≈20nm) were detected in a very 
low frequency (data not shown). As shown in the Western blot results from these fractions, 
f8-f11 contained three capsid proteins in the relative frequencies similar to the ones of wt 
AAV-2 capsid. Micrographs in the figure 2.11-C show that yeast-cell derived capsid-like 
structures (left) were morphologically similar to the ones obtained from 293 cells (right) 
(HEK293T cell-produced empty AAV2 capsids are a kind gift from Jurgen Kleindchmidt). 
The density of capsid positive fractions is far over the expected ones for empty AAV 
capsids produced in mammalian cells (approximately 1.32 g/ml) [241].  This could be 
explained in terms of a “heavier yeast extract” since all obtained fractions had higher 
densities than the corresponding fractions derived from AAV producing 293T cells (e.g. 
the lightest fractions were 1.37 for yeast and approximately 1.28 g/ml for 293T cells) 
[241]. This “heavy extract” might be the consequence of cellular impurities (e.g. remaining 
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chromatin; although the extract was treated with DNase the extract was still viscous when 
loaded on the sucrose cushion), ineffectively removed in the upstream processing steps. 
These steps are extremely laborious since a large cell biomass is used for capsid 
production (around one billion of cells). Beside, the sucrose remaining from the first 
ultracentrifugation and high concentration of salts in the resuspention buffer increase the 
density of assembly intermediate-containing solution. In such an ambient AAV capsids 
may tend to aggregate and thus separate as the fraction of higher density. Finally, an 
additional CsCl gradient centrifugation of capsid positive fractions should overcome the 
impurity and aggregation problem and unable better characterization of capsids. Yet, this 
step would significantly decrease the overall capsid concentration and requires 
improvements in the upstream steps and in total yield of capsids proteins. Another possible 
explanation for the unusual densities of capsid positive fractions could be the presence of 
the variegated capsid population with empty and full/partially full capsids. Several groups 
have already demonstrated that AAV capsid can encapsid te different DNA impurities. 
These includes both viral cap and/or rep-cap sequences [242, 243] as well as pieces of a 
host cell genome or prokaryotic DNA of plasmids used for viral production. Besides, 
Kronenberg et al. have shown that only full AAV2 capsids, but not the empty ones, 
externalize VP1-VP2 N-terminus, using the energy of the DNA encapsidation into 
preformed capsids [63]. According to these studies, an indirect way to see weather yeast 
produced AAV capsids contain also full particles, might be to test their reactivity with N-
terminus specific antibody (e.g. Ab A1, [53]). However this approach is hardly feasible in 
the case of low capsid yield since the percentage of DNA containing particles may be too 
low to be detected with such an approach.  
Immunoreactivity of yeast-derived particles with anti-capsid A20 antibody 
To support electron microscopy results, 3 possibly “VLP-positive” fractions were analyzed 
in Ab-A20-based dot-blot assay for testing immunoreactivity of yeast-derived particles 
with anti-capsid A20 antibody (Fig. 2.11-D). A20 is a widely used monoclonal antibody 
with the affinity for conformational capsid epitope and does not bind native capsid proteins 
[53, 216]. As shown in the Figure, all three fractions showed reactivity to A20 antibody, 
with the highest concentration of A20-reactive virus-like particle in f8+f9 fraction. 
2.4. Conclusions and future prospective 
A considerable body of data about yeast-expressed viral structural proteins, able to 
assemble into authentic and chimeric virus-like particles (VLPs), has been reported up to 
date, including the recent success in S. cerevisiae-based production of VLPs of human 
Parvovirus, B19, the “autonomous” relative of AAV virus. This encouraged us to consider 
the possibility of using yeast S. cerevisiae as an in vivo cell system for production of 
AAV2 VLPs, with physical and biochemical properties similar to those of AAV vectors 
produced in mammalian cells. To do this, two requirements had to be satisfied: the 
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simultaneous expression of at least two out three AAV structural proteins, VP1 and VP3 
that form the structure of infective virions, and, secondly, the intracellular stoichiometry of 
these proteins should be similar to the one found in AAV vectors produced by mammalian 
cells. The co-expression of VP1 and VP3 in RSY12 strain was achieved by stable cell co-
transformation with two high copy plasmids, one carrying “VP1 expression cassette” under 
inducible yeast promoter Gal1” and the other one harbouring “VP3 expressing”, genuine 
AAV cap gene under its cognate p40 promoter. VP3 protein expression from AAV p40 
promoter in yeast cells resembled the expression prfile of yeast glycolitic-promoters 
characterized by positive correlation with the cell growth rate during glucose-based growth 
and expression cessation upon carbon source exchange from glucose to galactose [226]. 
On the other hand, the pGal1 galactose inducible promoter, guiding VP1 protein 
expression, is a strong, inducible yeast promoter which yielded the first detectable amounts 
of VP1 protein, already 40 minutes after removal of repressor (glucose) and addition of the 
inducer (galactose) to the growth medium. Upon thism nimal induction time, the co-
transformed yeast cells synthesized small amount of VP1 protein while sustaining high 
VP3 intracellular level accumulated during the pre-induction growth on glucose. Although 
not exactly simultaneous, but rather consecutive expression of VP1 and VP3 proteins 
yielded the “correct” stoichiometry of their final intracellular concentrations. However, the 
“short induction” strategy was poorly reproducible since it was based on marginal VP1 
expression in the first moments of induction which, in turn, was prone to fluctuations even 
if the same inducing and growth conditions were used. Certain determinants of the 
induction start point, such as residual glucose concentration in the growth medium and 
actual state of the cells in the moment of induction nset (e.g stress caused by 
instantaneous starvation and deoxygenation during the water-wash step between nutrient 
exchanges) are hardly controllable with the flask-shake cultures, causing poor reliability of 
this strategy. These lead to adoption of another strategy “glucose + galactose, mixed 
culture approach”, the strategy commonly used for high-yield production of heterologous 
proteins in yeast expression system [165]. Some general characteristics of this strategy 
introduced significant improvements into our expression system such as: elimination of 
stressful and inconvenient water-wash step, sustained p40 promoter activity and better 
control of Gal1 promoter both by galactose-based upregulation and glucose-based 
repression. This resulted in simultaneous expression of VP1 and VP3 as long as glucose 
was present in the medium, thus enabling fine tuning of the relative VP protein levels by 
varying both induction time and the amount of glucose in inductive medium. The best 
results in terms of: i) “optimal, wt-like” VP1:VP3 ratio and ii ) experimental reproducibility 
and convenience (the shortest induction time), was obtained with keeping residual glucose 
(0.5%) concentration in reach galactose (5%) inductive medium. The “low glu-high gal” 
strategy seemed to satisfy all requirements for effici nt assembly of capsid proteins in 
multisubunit VLPs. To check this, we adopted a standard, two step-procedure for AAv 
capsid purification, composed of: and encouraged us to proceed to the next step, capsid 
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purification. This was done by implementation of a standard 2 step procedure that 
included: 1) precipitation of assembly intermediates from native protein extracts by high-
speed ultracentrifugation through 40% sucrose-cushion, followed by 2) capsid purification 
by fractionation in CsCl gradient. Already the first step revealed the unexpected presence 
of VP2 protein in VP1-VP3 containing assembly products. 40% sucrose cushion 
ultracentrifugation of the extract derived from yeast clone transformed with the “VP1 
expressing construct” showed that small amounts of VP2 and VP3 protein (not-detectable 
in the total cell lysates) were expressed  from this construct by means of “slipping 
ribosome” mechanism of alternative translation initiation from VP2-ACG and VP3-ATG 
start sites comprised in the “polycistronic” VP1 cDNA. Although expressed in low 
concentrations by this clone, VP2 and 3 were able to perform homo-oligomerization and/or 
hetero-oligomerization with the more abundant VP1 protein generating high molecular 
weight structures, precipitated after high-speed ultracentrifugation.  
Going back to assembly intermediates derived from co-transformed yeast cells, their  
characterization in the 2nd step CsCl ultracentrifugation, revealed only small percentage of 
AAV capsids with properties similar to the wt ones, obtained in couple of fractions of CsCl 
gradient. These properties included VP composition, capsid architecture (assessed by 
electron microscopy), physical, biochemical (high CsCl stability and stability during 
various processing steps) and immunological properties (reactivity to A20 antibody). 
However, great percentage of assembly intermediates concentrated in the 1st step 
ultracentrifugation were actually recovered in a form of insoluble aggregated material.  
The similar situation was seen in the first Baculovirus-Insect cell VP-expression system 
made by Ruffing et al. [215] where 3 VPs were expressed from separated ORFs (cDNAs), 
each one carrying mutations in the other two VP-start codons. Later on, the formation of 
insoluble aggregates in this system was circumvented by producing VPs from overlapping 
ORFs (a single transcriptional unit), suggesting that mutations introduced were probably 
the reason of poor capsid assembly or of their aggregation [138]. However, no such 
mutations were present in VP expressing constructs in our system.  
A common propensity of unassembled VP monomers to ass ciate with cellular structures 
has been documented in various recombinant backgrounds including: aforementioned 
Baculovirus-Sf9 system, in vitro system and HeLa cells, and is very prominent in our S. 
cerevisiae expression system. Besides, L1 monomers of HPV16 expressed and assembled 
in VLPs in yeast P.pastoris, showed the same tendency [195]. L1 association with cellular 
structures was probably exhibited through hydrophobic regions of unassembled monomers. 
Cellular membranes could serve as sites of “molecular crowding” which could assist 
monomer assembly in VLPs. Majority of cellular VP1 and VP3 protein expressed by yeast, 
were recovered from insoluble cellular aggregates. This suggests that yeast-expressed 
capsid proteins have similar membrane-binding affinities. However, even small differences 
in these affinities (due to different N terminal ext nsions of VPs) could result in such 
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relative concentrations of the three VP proteins, i these “crowding zones”, different from 
their overall intracellular stoichiometry that we document upon their denaturizing 
extraction. The impact of such alterations on the final concentration of assembled capsid 
probably gains significance in the case of low overall production levels of VPs in our 
expression system. Besides, it is also possible that AAV particles of non-wt stoichiometry 
could have different surface properties, with certain hydrophobic regions exposed on the 
capsid surfaces that may cause VLPs to attach to cellular membranes. Normally, wt AAV 
virions are soluble while their hydrophobic residues are buried in the capsid interior [244]. 
Furthermore, foreign protein localization to insoluble cellular aggregates is often 
associated with its ubiquitination and further targeting to proteasome for degradation. We 
tend to exclude this possibility for VP proteins expressed in RSY12 yeast strain, since 
there was no difference in the total amounts and the degradation profile of VP1 and VP,  
when expressed in HT393 mutant strain that lacks couple of main proteasomal subunits. 
These comparative experiments were performed in the starting phase of this project and 
due to mentioned lack of differences the mutant strain was abandoned.  
Finally, certain steps in the downstream processing (particle purification) could be 
additional limiting factors for the final capsid yield. Critical in this view is the glass bead-
based mechanical cell rupture with unknown affects upon AAV capsid adherence to these 
artificial surfaces. However, since this is one of the standard procedures for VLP 
purification form yeast cells, it is rather the efficiency of the cell rupture which is the 
critical factor of the capsid yield.    
To improve production properties of our yeast cell-based AAV VLP expression system 
various techniques can be employed, some of them being already under way. 
Overcoming methodological obstacles: 
Our S. cerevisiae VP expression system is dependent on the fine setting of growth 
conditions during two production phases: pre-inductive 2% glucose growth (more than 
12h) and 4.5h inductive growth in low glucose (0.5%)- high galactose (5%) medium. With 
the use of flask cultures and a shaking incubator, the indicated amounts of each nutrient 
present actually the starting concentrations and cannot be maintained as such during the 
whole culture, significantly affecting the final protein yield. Beside, due to a glucose 
exhaustion and accumulation of the metabolic by-products at the end of the pre-inductive 
phase, the cells have to be pelleted and culture mediu  exchanged, instead of simple 
addition of galactose. Albeit less stressful than water-wash starvation, the harvesting step 
can still cause significant environmental fluctuations which can be differentially sensed by 
the cells in the population creating a sort of “variegated” system [245]. In such a system, 
following galactose induction could have different kinetics among cells in the population. 
If the residual glucose and high galactose levels could be kept constant in all cells of the 
population during extended culture growth, a prolonged ”induction” would result in a 
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multifold increase of both VP1 and VP3 levels. This can be achieved by implementation of 
novel technologies such as the chemostat continuous culture system to provide steady-state 
conditions and constant growth rates [246]. This can be achieved by adjusting the flow rate 
of fresh medium (with precise amounts of each nutrien ) into the growth chamber, 
providing a defined environment amenable to high-yield production [247]. The other 
system which offers the same benefits of constant feeding, acidity and culture oxygenation, 
is so called fed-batch cultivation in bioreactors (fermentors) [179]. 
Expression of AAV assembly activating protein (AAP)  in yeast:  
Another strategy to test in order to meliorate the efficiency of AAV capsid assembly in 
yeast cellular environment is to test weather AAP protein, co-expressed with VPs and/or 
overexpressed from the separate plasmid, could exhibit the same assembly promoting 
effect seen in mammalian cells [64]. Since expression from CTG initiator is very rare and 
inefficient in  yeast cells, AAP was not expected to be expressed in its natural genomic 
configuration (e.g. from YplacRepCap construct). Indeed, when we cloned the authentic 
cDNA of AAP gene in the separate plasmid, under strong Ga1 promoter, no protein was 
detected. Instead, we have recently changed the AAP’s CTG initiator to the  conventional 
ATG one, in the same plasmid, in frame with the FLAG tag sequence for the visualisation 
of the fusion protein. Protein expression analysis is currently under investigation. 
“Yeast-izing” AAV cap gene: 
When a recombinant protein is not expressed to a sufficient level, the first “solution” that 
comes to a head of an average researcher is: “let’schange the promoter”! This is not 
surprising since “expression = promoter” used to be a concept of recombinant DNA 
technologies for many years. However, translational and post-translation regulations of 
protein expression significantly differ between evoluti nary distant species, such as yeast 
and other metazoan. Differences in the abundance of iso-accepting tRNAs that resemble 
the relative frequencies of synonymous codons, are obs rved between organisms, and also 
between the tissues of a given organism, and are postulated as one explanation for “why 
the same gene is more or less efficiently translated in different organisms and organs” 
[248-250]. The codon usage bias between the viral and the host cell genome is shown to be 
an important determinant of viral protein expression within the host cell [251]. 
Virus genomes frequently have a G+C content significantly different from that of their host 
species, reflecting a different codon usage pattern [251, 252]. Similarly, the GC 
composition of AAV genome and S. cerevisiae genome is tabulated. Table shows that GC 
content in AAV2 and S. cerevisiae genomes are quite different ranging from 40.65–
67.53% and from 36.64–44.58%; frequencies in the 3rd letter of the codons are strikingly 
different suggesting great codon usage bias between these two species.  
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Table2.4. Comparison of the G/C content in the genomes: Total GC composition and the GC 




1st (%) 2nd (%) 3rd (%) 
S. cerevisiae 39.77 44.58 36.64 38.10 
AAV2 54.73 56.01 40.65 67.53 
Analysis of codon frequencies between yeast and Cap coding region revealed that 14 most 
frequently used codons in AAV cap gene are more than wice as frequent as the ones in 
yeast genes.  Low abundance of iso-accepting tRNA for these codons, at least in part, 
underlies low expression of the VP proteins in thissy tem. Codon optimization of cap gene 
sequences, or “yeast-izing” the AAV genes, so that t ey can reflect more closely the codon 
usage of the host (yeast), should maximize the expression of the “optimized” gene and is 




3. PROJECT II:  Formation of AAV single stranded DNA 
genome from a circular plasmid in Saccharomyces 
cerevisiae  
3.1. The aim of the project 
In the first part of this work, we demonstrated for the first time, that yeast is able to form 
AAV2 capsid like particles. As the final aim of the entire lab project is to use yeast as a 
host to produce rAAV vectors able to infect human cells, we have also studied the ssDNA 
formation and replication in Saccharomyces cerevisiae nd the mechanism underlying this 
process.  
3.2. The background of the project 
3.2.1. AAV replication in the recombinant background 
The most important function (and the origin of the name) of the two largest Rep isoforms, 
Rep78 and Rep68, is the regulation of AAV-2 replication during the proliferative phase of 
AAV2 life cycle. They perform this function via their interaction with Rep-binding 
element (RBE) and terminal resolution site (trs) sequences located within the ITRs. 
Besides, these two Rep isoforms guide site-specific integration of AAV genome during the 
latent phase of the virus life cycle  [28-31]. The small Rep protein species, Rep52 and 
Rep40 are involved in the generation and accumulation of ssDNA viral genomes from 
double-stranded replicative intermediates [32, 33, 47, 48]. Since functions of two large and 
two small Rep proteins are overlapping, one of each (Rep78 and 52 or Rep68 and 40) has 
to be provided in trans to enable replication and packaging of ‘gutless’ AAV vectors (ITRs 
flanking the gene of interest) in the recombinant background. Although helper virus 
functions are compulsory for rAAV2 replication in ma malian cells, this is not the case 
with Insect cells. Either these cells, or Baculovirus used to introduce rAAV genomes, seem 
to provide all necessary factors for efficient rAAV replication in the presence of Rep 
proteins [138, 145, 146]. Previous studies using yeast two/one hybrid system have shown 
that yeast expressed Rep 78/68 proteins retain their RBE site specific, binding activity, 
which is the first step in establishing their role in promoting replication of rAAV genomes 
[229]. Weather this role can be completed upon rAAV introduction in yeast cells is the 
leading question of this project and will be addressed in this chapter.  
3.3. Results  
(The most of results in this section have been recently published by our group; Ref [253] ) 
3.3.1. Rep68 increases the frequency of yeast clones contai ing the AAV 
genome. 
To explore whether the yeast Saccharomyces
AAV genome from a plasmid containing the ITRs, we constructed the pAAVRepURA3 
vector containing the wild type rep gene and the URA3 marker flanked by the ITRs 
(Fig.3.1A) and the pAAVpokURA vector which does 
only URA3 gene and the stuffer sequence, pok (Fig. 
  
Figure 3.1. Schematic representation of plasmids.
(A) The vector pAAVRepURA contains wild type Rep 
gene flanked by the two ITRs. B) The vector pAAVpokURA contains a stuffer sequence, pok, instead of 
gene. The ITRs are the only AAV sequence present in the vector. C) The vector pRepURA has the same 
sequences as pAAVRepURA without ITRs. 
With the vector pAAVpokURA, we wanted to determine whether the internal Rep 
sequence could affect ssDNA formation. These vectors d  not share any homology to the 
genome of the RSY12 strain which harbors the complete d letion of the chromosomal 
URA3 gene [254]. Moreover, as pAAVRepURA3 and pAAVpokU
yeast replication origin such as ARS or 2 micron, 
colonies unless the vector integrates 
chromosomally. The pAAVRepURA3 and pAAVpokURA were co
strain RSY12 with the plasmid containing the Rep68 expression cassette, or with the 
control plasmid pGAD424. The plasmids pGAD424 and pGRep68 carry the LEU2
yeast selection marker. As shown by counting the number of colonies grown onto the 
plates with medium lacking both uracil and leucine
URA3+LEU2+ colonies increased from 3.05±1.1x10
to 91.7±43.6x10-3 (pAAVRepURA3 with pG.Rep68). 
Similarly, the frequency of URA3+LEU2+ colonies rose
(pAAVpokURA with pGAD424) to 63.3±19.4x10
(Fig. 3.2B). 
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 cerevisiae is able to sustain the rescue of the 




gene and the yeast URA3 marker replacing the Cap 
Rep
RA do not carry any 
thus, they cannot give rise to URA3 
in the yeast genome or replicates extra 
-transformed into the 
 gene as 
 (Fig. 3.2A), the frequency of 
-3 (pAAVRepURA3 and pGAD424) 
 
 from 18.1±5.2x10-3 
-3 (pAAVpokURA with pG.Rep68) 
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Figure 3.2: The frequency of colonies carrying 
The plasmid pAAVRepURA3, pAAVpokURA linearized with 
digested with XbaI, were co-transformed with the plasmid pGAD424 or pG.Rep68 containing the 
marker gene (A, B). (A) Representative plates comparing colonies o
strain with plasmid pRepURA and pGAD424 (i), pRepURA and pG.Rep68 (ii), pAAVRepURA and pGAD424 
(iii); pAAVRepURA and pG.Rep68 (iv). (B) Transformed yeast cells were scored for their ability to form 
colonies on selective medium lacking leucine and uracil. The frequency was calculated as described in material 
and methods. Results are the mean of 4 independent experiments±standard 
The expression of Rep68 did not change the frequency of URA3+LEU2+ colonies whe
yeast was transformed with the plasmid pRepURA3 which does not contains the ITRs (fig 
3.2B). These results suggest that the effect of the Rep68 is related to the presence of ITRs 
and that Rep68 may be important for AAV replication a d
human cells. 
3.3.2. Expression of Rep proteins 
Rep protein expression from natural AAV2 promoters, p5 and p19, preserved in rep 
gene of pAAVRepURA constructs. 
Similarly to YplacRepCap plasmid, where 
promoter in their wt genomic configuration, the same result was obtained for 
pAAVRepURA vector where complete Rep coding region 
analyses (Figure 3.A) showed that the distribution of Rep proteins to pr




rAAV genome increase when Rep68 is expressed. 
PvuII and the control plasmid, pRepURA3, 
LEU2 
btained from the transformed yeast RSY12 
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Rep40 are present both in the extract 1 (fig.3.3A, lane1) and extract 2 (lane2), while Rep78 
is observed only in the second protein extract (Fig3.3A, lane2). Rep68 is not observed. 
Rep68 protein expression from Constitutive Yeast ADH1 Promoter  
The properties and schematic of pG.Rep78 was already represented in the chapter 2.3 (see 
fig.2.2A). pG.Rep68 was made in the same way as p.G Rep78, by placing Rep68 cDNA 
under truncated version of yeast ADH1 promoter. Originally, these plasmids were made 
for the use in yeast one-hybrid system where expression of large Rep proteins was 
demonstrated indirectly by Rep78/68 mediated transcriptional activation of reporter gene 
expression, while, according to the author, these proteins couldn’t be detected by the 
Western Blot analysis. In our hands, in RSY12 strain background, Western Blot analysis 
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Figure 3.3: Western blot analysis of the Rep protein expression in yeast. 
(A) Distribution of Rep proteins in two protein fractions (extract1 and extract2/insoluble fraction) derivd from 
cells transformed with pAAVRepURA. (B) Analysis of Rep proteins present in the extract2 of lysates derived 
from cells transformed with pG.Rep68 plasmid (lane2) and from RSY12-R68 clone carrying 2 integrated 
copies of ADH-Rep68 expression cassette (lane3). Extracts from pGAD (empty vector) transformed cells were 
used as -control. Loading control: Constitutive yeast protein 3PGK. 
Results for pG.Rep68 are shown in the figure 3.3B. Besides, just like for pG.Rep78, p19 
regulated coding region comprised in Rep68 cDNA gave rise to Rep 40. As expected, 
Rep68 was mainly found in insoluble protein fraction, extract2 (fig.3.3B, lanes2), while 
Rep40 was almost equally distributed between the first and the second protein extract 
(fig.3.3B, lanes1, 2). In the lane 3 of the fig.3.3B we present the relative amount of the rep 
proteins expressed form the yeast clone carrying the pADH-Rep68-tADH expression 
cassette randomly integrated in the yeast genome. Comparing to RSY12 cells transformed 
with multicopy (more than 20 copies) plasmid harboring the Rep gene,  apparently smaller 
amount of Rep proteins corresponds to 2 copies of Rep68 cDNA detected by the Southern 
blot analysis of the genomic DNA derived from this cell clone (Southern blot data not 
shown). However, this cell clone stably expressed rep proteins after many repeated growth 
cycles in the complete growth media (without selection).  
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3.3.3. AAV ssDNA formation in yeast 
The AAV genome inserted into a plasmid vector can initiate a productive AAV replication 
when it is transfected in human cells that are simultaneously or subsequently infected with 
a helper virus. The AAV genome is released from a circular plasmid in a way that is 
similar to the rescue of the integrated AAV provirus in latent phase [19]. It has also been 
observed that the rescue of the AAV genome in HeLa cells extracts is more efficient when 
the Rep68 protein is expressed [26]. We, therefore, ch cked if Rep proteins expressed from 
pAAVRepURA were sufficient to rescue AAV genome from the circular plasmid in yeast. 
To do so, low molecular weight (Mr) DNA from URA3+ yeast clones transformed with the 
pAAVRepURA was analyzed by Southern blot and probed with URA3 gene to check for 
the presence of rescued ssDNA, which is expected to be about 3kb (Fig. 3.4A). As we 
observed a band with a molecular weight higher than 10kb, we concluded that rescue did 
not occur and that the URA+ phenotype is determined by integration of the vector in the 
genomic DNA. We therefore, analyzed the genomic DNA extracted from these clones, 
after digestion with AseI. This enzyme cuts the pAAVRepURA backbone in two sites but 
not the AAV sequence (Fig. 3.4G). The analysis revealed the presence of multiple (fig 
3.4B and C, lane 2, or single integrated genomes (fig 3.4B and C, lane 4). This result 
suggests that a certain level of Rep proteins might be necessary to keep the 
pAAVRepURA plasmid replicating autonomously inside the yeast cell. The Rep protein 
expression can be directed by the AAV natural promoters p5 and p19, as already shown, 
but if AAV replication in yeast occur in Rep dependt manner, we hypothesized that rep
gene should be located in another vector in order to provide a certain amount of Rep to 
initiate the AAV genome replication. It is likely that the pAAVRepURA vector is 
maintained as an episome only when Rep proteins reached quite high level of expression. 
To verify this hypothesis, we transformed yeast cells that have the pAAVRepURA 
integrated in the genome with the plasmid pG.Rep68. Two of the transformed 
URA3+LEU2+ clones were subjected to the extraction of low Mr DNA from and analyzed 
by Southern blot. This analysis revealed the presence of only a band of ~6kb in one clone 
(Fig. 3.4D, lane 1) and a band with a molecular weight higher than 10kb in the another 
clone ( Fig. 3.4D, lane 2). The band of 6kb could be due to a plasmid excision event 
occurring by intrachromosomal recombination that has been reported to occur at high 
frequency in haploid yeast strain [255, 256]. We, then, investigated the possibility that 
AAV ssDNA rescue took place after the co-transformation of pG.Rep68 and 
pAAVRepURA. Under these experimental conditions, yeast may have a sufficient level of 
Rep proteins, necessary to induce AAV ssDNA rescue from the transformed plasmid. Low 
Mr DNA was extracted from several independent clones, digested with DpnI and analyzed 
by Southern blot using the URA3 as a probe. DpnI digestion allows discriminating 
between DNA replicated in yeast from that replicated in bacteria because it cleaves only 
double-stranded sequences methylated or hemimethylated by Dam methylase. As shown in 
the figure 3.4E in two clones transformed with the pAAVRepURA and the empty pGAD, 
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we mainly observed that the highest band is digested by DpnI (Fig. 3.4E, lane 2 and 4). 
This band may correspond to the transformed plasmid; the other band, higher than 10kb, 
resistant to DpnI digestion, corresponds to genomic DNA; in fact, probing low Mr DNA 
from the same clones with the genomic marker ADE2, the same band was observed (data 
not shown). In the two clones, no band corresponding to ssDNA was observed. On the 
contrary, when we analyzed the low Mr DNA extracted from yeast cells co-transformed 
with pAAVRepURA and pG.Rep68, four main bands were observed: a band higher than 
10kb that is genomic DNA, a band of about 10kb, andtwo smaller bands of about 5.5kb 
and 2.5-3kb (Fig. 3.4F, lanes 1, 3, 5, 7). The DpnI restriction did not change the band 
pattern, but determined a decrease in intensity of the 5.5kb band and an increase in 
intensity of the 10kb band consistent with a nicking activity of DpnI (Fig. 3.4F, lanes 2, 4, 
6, 8). Since the plasmid pAAVRepURA contains 27 DpnI sites (Fig. 3.4G) and some of 
them are really close to each other (less than 10 nucleotides apart), nicking of one or more 
sites may result in a modification of the tertiary DNA structure leading from a supercoiled 
circle (5.5kb) to a nicked one (10kb). Moreover, pAAVRepURA has a region of 
approximately 2kb including the URA3 gene, which is free of DpnI sites (Fig 3.4G). Thus, 
if DpnI restriction had occurred, we would have observed the 2kb band corresponding to 
URA3 gene, as seen in the case of the plasmid pAAVRepURA extracted from bacteria 
(Fig.3.4E, lane 5). These results strongly suggest the presence of newly replicated 
episomal DNA in yeast clones. The 2.5-3kb band was not restricted by DpnI suggesting 
that it is a product of the new replication and could be the ssDNA rAAV2 genome (Fig 
3.4F, lanes 2, 4, 6, 8). The molecular weight corresponds to the ssDNA progeny of AAV 
observed by Wang et al. [257]. Further demonstration that the three bands are the product 
of new replication of the plasmid DNA is presented in figure 3.5A and B. Low Mr DNA 
extracted from one clone shown in Fig.3.4G is digested with the MboI restriction enzyme 
which recognizes the same palindromic sequence as DpnI but cleaves only non-methylated 
























Figure 3.4: AAV replication in yeast. 
 (A) Southern blot analysis of low Mr DNA of two different yeast clones URA3+ (lane 1 and 2) derived from 
transformation with pAAVRepURA3 using the URA3 marker gene as probe. (B, C) Southern blot analysis of 
genomic DNA of the same two clones as in B undigested (lane 1 and 3), and digested with AseI (lane 2 and 4) 
probed with URA3 (B) or ITR probe (C). (D) Low Mr DNA of the two yeast clones URA3+LEU2+ derived 
from transformation with pAAVRepURA3 and successively transformed with pG.Rep68 (lane 1 and 2) 
analyzed on Southern Blot using the URA3 probe. (E) Low Mr DNA of yeast clones URA3+LEU2+ derived 
from co-transformation of pAAVRepURA with control plasmid pGAD424. Lanes 1 and 3 show the undigested 
DNA and lanes 2 and 4, DNA digested with DpnI and subjected to Southern blot analysis using URA3 marker 
gene as probe. Lane 5 shows the result of DpnI digestion of the pAAVRepURA plasmid. DpnI was performed 
in order to demonstrate that AAV DNA replicated in yeast. (F) Low Mr DNA of yeast clones URA3+LEU2+ 
derived from co-transformation of pAAVRepURA with plasmid pG.Rep68. Lanes 1, 3, 5, 7 show the 
undigested DNA and lanes 2, 4, 6, 8 DNA digested with DpnI and subjected to Southern blot analysis using 
URA3 marker gene as probe. (G) Schematic representatio  of DpnI/MboI (indicated with D) and AseI 
(indicated with A) restriction map of pAAVRepURA plasmid. The DpnI/MboI restriction endonucleases do not 
cut in the URA3 gene. 
The not digested DNA shows the same bands when probed with URA3 (Fig 3.5A, lane 1) 
or ITR (Fig 3.5B, lane 1) suggesting that it contais the complete sequence of recombinant 
AAV. Digestion with MboI enzyme degraded completely the 10kb and the 5.5kb bands 
and produced the 2kb band detected with URA3 probe (Fig.3.5A, lane 3) and not with ITR 
probe (Fig.3.5B, lane 3), suggesting that these bands represent mainly newly replicated 
DNA. The 2.5-3kb molecule is only partially digested by MboI and not completely 
degraded as the other bands. This observation does not rule out the possibility that the band 
represents the ssDNA because it has been demonstrated hat some restriction enzymes, 
including MboI, are able to cut ssDNA [258, 259].  
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Characterization of ssDNA 
In order to ascertain that the lowest band corresponds to ssDNA AAV genome, we 
exposed the extracted DNA to the single-stranded DNA-specific S1 or Mung Bean 
nuclease. Low Mr DNA digested with these two enzymes was analyzed by Southern blot 
and probed with URA3 or ITRs. As shown in figure 3.5, in the lanes where the DNA 
samples treated with the S1 nuclease were loaded (Fig. 3.5A, lane 4; fig 3.5B, lane 4) the 
2.5-3kb band is not present. The same result was observed when the DNA was treated with 
Mung Bean nuclease (Fig. 3.5C, lanes 2 and 4). Importantly, when the probe “ITRs” was 
used in the Southern blot (Fig. 3.5B), the three bands were again obtained, demonstrating 
that these replication-essential DNA elements are present. 
 
 
Figure 3.5: S1 and Mung Bean nuclease sensitivity. 
(A, B) Low Mr DNA from a URA3+LEU2+ clone derived from co-transformation of pAAVRepURA with 
plasmid pG.Rep68, was digested with DpnI (loaded in the lane 2), MboI ( loaded in the lane 3) , S1 nuclease 
(in the lane 4) and was analyzed on Southern Blot using URA3 probe (A) or ITR probe (B). (C) Southern blot 
analysis of low Mr of twoURA3+LEU2+ clone derived from co-transformation of pAAVRepURA with 
plasmid pG.Rep68 was digested with Mung Bean nuclease (in the lane lane 2 and 4) and compared with the not 
digested DNA (lane 1, 3). DNA was detected using the URA3 probe. The arrows indicate the ssDNA which 
disappeared after digestion with S1 and Mung Bean nuclease. 
Characterization of the replicated rAAV  
During the rescue of AAV from plasmid in 293T cells, it is possible to isolate the linear 
double-length double-stranded DNA molecules and the DNA double-stranded single copy 
[257]. According to the AAV DNA replication model, the secondary structure formed by 
the ITRs provides a free 3' hydroxyl group for the initiation of viral DNA replication via a 
self-priming strand-displacement mechanism involving leading-strand synthesis and 
double-stranded replicative intermediates monomer formation (Fig.3.6F,i).  
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Figure 3.6: Characterization of newly replicated DNA
 (A) Low Mr DNA of four clones derived from yeast co
digested with DpnI and BamHI (lane 2, 4, 6, 8) and not digested (lane 1, 3, 5, 7) was analyzed on Southern Blot 
and probe with the URA3 gene. BamHI cuts once in A
obtained from the cotransformation of pAAVRepURA with pGAD not digested (lane 1) and digested with 
DpnI and BamHI (lane 2); the low Mr DNA of one out four clones analyzed in panel A undigested (lane 3) and 
digested with DpnI and BamHI (lane 4) was analyzed on Southern Blot and detected with URA3 probe (B) and 
F1 probe (C). (D, E) Equal amount of low Mr DNA of one 
gel slots and transferred on nylon membrane. The membrane was cut in two pieces corresponding to gel slots 
and further cut to leave only ssDNA. The ssDNA was detected using as probe a 100
complementary to the filament (+) of the URA gene
filament (-) of the URA gene, URA(-) (E), to determine the polarity of ssDNA. (F) Restriction maps of 
predicted replicative intermediates: i) linear monomer, ii) tail
vector. B indicates position of BamHI. The sizes of the fragments liberated following 
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These structure is resolved at the trs by site-specific nicking of the parental strand opposite 
of the original 3' end position (i.e., at nucleotide 125) leading to the formation of ssDNA. 
When nicking does not occur, elongation proceeds through the covalently closed hairpin 
structure generating linear double-length double-stranded molecules with either a tail-to-
tail configuration (Fig.6F,ii) or a head-to-head configuration (Fig.3.6F,iii) [22]. To 
determine the structure of molecules replicated in yeast, we digested low Mr DNA with 
BamHI that cuts pAAVRepURA only once in rep sequence at 1kb (Fig. 3.6F, i).  If the 
newly replicated molecules would be generated according to AAV replication model 
observed in human cells, the BamHI digestion of lowMr DNA detected with URA3 probe, 
would produce a band of 3.5kb in case of linear monomer (Fig.3.6F, i); a band of 7kb in 
case of tail to tail dimer (Fig.3.6F,ii); a band of 3.5kb in case of head to head (Fig.3.6F,iii). 
As shown in Fig.3.6A, no one of these molecules was produced, but rather we found only 
one band of ~ 8kb (lanes 2, 4, 6, 8) which is the siz of the linearized plasmid containing 
the backbone and AAV genome (Fig. 3.6F, iv).To confirm this hypothesis, we digested 
with BamHI the low Mr DNA isolated from a URA3+LEU2+ clone carrying 
pAAVRepURA plus pGAD (Fig. 3.6B, lane 2; fig. 3.6C, lane 2) or pAAVRepURA plus 
pG.Rep68 (Fig.3.6B, lane 4; fig.3.6C, lane 4) and hybridized with the F1 probe (Fig.3.6B) 
that recognizes F1 origin of replication, located in the backbone of the plasmid, or with the 
probe URA3 (Fig.3.6C) that recognized the URA3 sequence in the AAV vector. As shown 
in the figure 3.6B and 6C, the bands obtained with F1 probe are coincident with those 
obtained with URA3 probe. The results of the BamHI digestion produce a band of ~8kb 
recognized by URA3 and F1 (Fig 3.6B lane 4; Fig 3.6C, lane 4). This observation indicates 
that the band of 5.5kb corresponds to the supercoild pAAVRepURA and the band of 10kb 
corresponds to the nicked circular form. Moreover, the ssDNA molecules band is 
recognized by both probes indicating the presence of tw  different molecules, one 
containing AAV sequences and one with vector sequences. To determine the polarity of 
ssDNA, we detected the ssDNA with two oligonucleotides probes complementary to 
filament +, URA(+) (Fig. 3.6D) or to filament - URA(-) (Fig. 3.6E). As shown in figure 
3.6D and E both the plus and minus strands of ssDNA are generated. 
ssDNA formation is independent of AAV Rep sequence and dependent on ITRs. 
Recombinant AAV vectors do not contain AAV genome sequences but only the transgene 
that can be used for gene therapy in human cells. It has been shown that a region of the 
AAV2 rep gene acts as a cis-acting Rep-dependent element able to promote the replication 
of transiently transfected plasmids [260, 261]. To investigate whether the formation of 
ssDNA was dependent on the presence of rep sequence in th  vector, we constructed the 
pAAVpokURA that has URA3 gene and a stuffer sequence (denominated “pok”) flanked 
by the two ITRs (Fig. 3.1B). In total, the sequence that corresponds to the recombinant 
AAV genome is 4.1kb. This vector was transformed in yeast clone expressing Rep68 from 
an integrated copy of pG.Rep68 plasmid. Low Mr DNA was isolated, treated with S1 
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nuclease to ascertain the presence of ssDNA and Southern Blot analyzed. As shown in the 
fig. 3.7A lane1, the ssDNA is produced.  
A  B 
Figure 3.7: ssDNA formation is dependent on ITRs and Rep68. 
Southern blot of low Mr DNA obtained from a clone expressing Rep68 transformed with pAAVpokURA (A) 
or pRepURA (B) and probed with URA3. (A) Lane 1 shows low Mr DNA undigested and lane 2, low Mr DNA 
subjected to S1 nuclease. (B) Low Mr DNA of two different clones (lane 1 and 2) expressing Rep68 and 
transformed with pRepURA. 
The two bands corresponding to ssDNA could represent two different secondary structures 
of the molecule. This suggests that the formation of ssDNA is not dependent on RBE in the 
rep gene, but only on ITRs. To verify if the ITRs are involved in the formation of the 
newly replicated molecules and the ssDNA, we constructed the vector pRepURA. This 
vector contains the same sequences as pAAVRepURA but not the ITRs (Fig. 3.1C). 
pRepURA was transformed in the yeast clone expressing Rep68. Two resulting 
URA3+LEU2+ clones were subjected to low Mr DNA extraction and subsequent Southern 
blot analysis (Fig.3.7B, lanes 1, 2). As shown in figure 3.7B, neither circular DNA 
molecule nor ssDNA was generated in these clones, i the presence of Rep68. 
3.3.4. Expression of Adenovirus helper factors E1b55K and E4orf6 in 
yeast cells and their influence upon rAAV ssDNA formation in the 
presence of Rep 
In human cells productive AAV-2 replication occur only in the permissive cellular 
environment characterized either by the presence of one of the helper viruses, such as 
Adenovirus (Ad) , Herpes Simplex Virus (HSV) or Human papilloma virus (HPV) or by 
the presence of various physical and chemical agents causing genotoxic stress (see chapter 
1.1.3). The helper activities provided by Ad were the most extensively studied and 
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previous studies have delineated a minimal set of Ad proteins required for replication that 
includes: E1A, E1b55K, E4orf6, and DNA-binding protein (DBP). E1b55K and E4orf6 act 
as a complex to enhance rAAV transduction and wt AAV replication through overcoming 
barriers to second-strand synthesis of the genome by still elusive mechanism [70]. 
E1b55K/E4orf6 has also been shown to form a cullin-co taining ubiquitin ligase to 
promote degradation of the Mre11 complex, DNA ligase IV, p53 and Bloom Helicase 
during Ad infection [262, 263]. Degradation of these host cell targets prevents apoptosis, 
DNA damage signaling, and viral genome processing during Ad infection [263, 264]. In 
addition, E1b55k is the only Adenovirus protein found to associate directly with Rep68/78 
[79].  
In order to create the best cellular conditions for the AAV ss DNA formation in yeast, we 
expressed E4orf6 and E1b55k Ad proteins under two galactose inducible promoters from 
Gal1-10 family and analyzed their putative influenc on AAV replication intermediates, in 
the presence of Rep 68 protein in RSY12 yeast cells. Both E4orf6 and E1b55k genes were 
inserted in a single plasmid pEsc-G418 under control of Gal1 and Gal10 promoters, 
respectively, and the resulting construct pEscE4E1b was used to transform yeast clone that 
carries Rep68 gene integrated in its genome. As shown in the figure 3.8 two proteins were 
expressed not only in presence of galactose but also under non-inductive conditions (when 














Figure 3.8: Effect of the expression of E4orf -E1b55k on ss DNA formation. 
(A, B) Western blot analysis of E4orf6 and E1b55k protein xpression in the RSY12-R68 clone carrying 
endogenous ADH-Rep68 gene and transformed with pEscE4E1 contrast, using the mAb against E4orf6 (A) or 
the mAb anti Flag antibody which recognizes Flag tag fused to E1b55k (B). Cells were grown over-night in 
glucose (glu) and then switched for 6h induction in galactose (gal) medium. E4orf6 and E1b55k expression 
68 
was analyzed at the end of both glu and gal growth phases. Protein extract from RSY12 clone transformed with 
the empty vector pEscG418, collected after growth in galactose were used as a negative control (-contr.). 
Loading control: Constitutive yeast protein 3PGK. (C) Southern blot analysis of low molecular weight DNA 
isolated from  the RSY12-R68 clone transformed with the pAAVpokURA vector (lane 1), and from RSY12-
R68 clone transformed with both pESCE4E1 plasmid and pAAVpokURA vector (lane 2). Both clones were 
grown in galactose. URA3 gene was used as probe.   
A yeast clone expressing Rep68 and E4orf6-E1b55k was subsequently transformed with 
the pAAVpokURA vector and the transformed cells were g own in presence of galactose 
before the isolation of Hirt DNA. The production of ssDNA was analyzed by Southern blot 
(Fig. 3.8C, lane 1). In presence of E4orf6-E1b55k the amount of ssDNA increased with 
respect to the clone that lacks Ad helper functions, while other replication intermediates 
remained unchanged (Fig. 3.8C, lane 2).Weather this effect in yeast is a reminiscent of the 
MRN complex degradation promoted by these proteins in human cells, is the subject of 
current investigations.  
3.4. Conclusion and future prospective  
The results reported here establish the novel finding that the AAV ssDNA is formed in 
yeast from a double stranded circular plasmid containi g the ITRs. Moreover, the plasmid 
is maintained throughout the generations as a double stranded circle in the absence of the 2 
micron replication origin or ARS sequence. Initially, we simply constructed an AAV 
vector containing the wild type rep sequence and the URA3 marker between the two ITRs, 
in order to select yeast clones carrying the rAAV. Interestingly, we demonstrated that Rep 
protein expression occurs in yeast starting from the AAV promoter p5 and p19 (Fig. 3.3A). 
The failure to obtain the ssDNA genome when yeast was transformed only with 
pAAVRepURA vector is likely due to the absence of Rep protein at the moment of 
transformation; in fact, when Rep protein was expressed from pG.Rep68 plasmid, 
transformed together with high amount of AAV vector, the frequency of URA3+LEU2+ 
colonies was increased. The transforming DNA carrying the rAAV could follow different 
ways: it could be recognized by the DNA nucleases and degraded, or be channeled in the 
recombination process and consequently integrated in the host cell genome. The 
transforming rAAV plasmid could also be replicated and the AAV genome be rescued 
from the plasmid. The latter process can occur onlyin the presence of Rep68 [26]. To test 
the hypothesis that ssDNA may be generated by plasmid replication, we cotransformed the 
rAAV vector with pG.Rep68, allowing the expression of Rep68 and Rep40 (Fig. 3.3B) to a 
sufficient level in the moment of cell transformation with high concentration of rAAV. In 
these conditions, ssDNA was generated, as shown in figure 3.4F. Moreover, we also 
demonstrated that the ssDNA is formed only when the ITRs are present (Fig. 3.7B, lane 1 
and 2). By using both in vivo and in vitro experimental systems, the principal features of 
the conventional AAV rescue model have been shown to i clude the synthesis of duplex 
linear replicative forms (monomers and dimers) thatare self priming by virtue of terminal 
hairpin palindromes [257, 265, 266]. Two sort of mechanisms have been proposed to 
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explain rescue of AAV in human cells: rescue may be carried out by repair cellular 
nucleases [21, 267, 268] or it may be coupled to DNA replication [21], [26, 269]. It has 
been observed that rescue of the AAV genome from a plasmid may be carried out by a 
Holliday structure-resolving activity in vitro [270] and in vivo [271]. In any case, the 
episomal DNA is not produced by the “AAV rolling hairpin” type of DNA replication 
since the analysis of the structures of low Mr DNA molecules (Fig. 3.6) didn’t reveal the 
canonical AAV replicative intermediates, but rather the replicated, supercoiled and nicked, 
circular plasmid and the ssDNA. Moreover, these molecules contain not only ITRs and 
URA3 sequences, but also vector sequences. The fact th t not only AAV sequences but 
also plasmid backbone sequences are displaced as ss DNA, prone to be  packaged in AAV 
capsids, could limit the potential of the yeast system for studying rAAV genome packaging 
and/or its application for AAV vector production. However, a similar problem has been 
already encountered in mammalian cells where a significa t portion of the encapsidated 
DNA is derived from the ITR-containing rAAV vector plasmid, arising from ‘reverse’ 
packaging from the ITRs [272]. It was demonstrated that this problem could be at least 
diminished, if not resolved, by designing ‘oversized’ plasmid backbone, that is, exceeding 
the 4.7 kb natural packaging limit of AAV. We believe that the use of the same strategy 
can prevent potential packaging of yeast plasmid back ones in  AAV capsids. The 
persistance of the whole ds rAAV plasmid and of its ss backbone sequences suggests that 
the entire plasmid is replicated as circle from which ssDNA is released. To explain the 
production of ssDNA genomes without generating linear duplex intermediate, we propose 
a model outlined in the figure 3.9. According to our model, Rep68 binds the ITR at the 
RBE element and nicks one strand at the level of trs (Fig. 3.9A). The nick creates a free 3’-
OH end, from which DNA replication is initiated (Fig. 3.9B) [32]. As the replication 
passes through the body of ITR (Fig. 3.9C), the partially single stranded template strand 
will fold into a hairpin configuration (Fig. 3.9D). This folding of the ITR template may be 
supported by Rep binding to the tip of the hairpin loop of the ITR [268]. This event 
produces a strand switch and the template is likely to be the nicked strand and not the 
complementary one. The replication fork proceeds through the vector sequence and 
terminates when reaches the nicked ITR. A second nick by Rep protein occurs at the level 
of the newly synthesized ssDNA that is, subsequently, displaced by the helicase activity of 
Rep proteins (Fig. 3.9D). The ssDNA molecule containing the entire plasmid sequence is 
nicked by Rep protein (Fig. 3.9E). The final products are two ssDNA molecules containing 
only one ITR; one with vector sequences and one with rep and URA3 genes (Fig. 3.9F). 
Our model predicts that the resulting ssDNA genome with AAV sequences has a complete 
ITR only at the 5’ end while the 3’ end carries only a D element. The missing ITR, 




Figure 3.9: Model of ssDNA formation from a plasmid containing rAAV genome in yeast. 
(A) For the sake of clarity, the plasmid caying ITRs is depicted as linear molecule. Rep nicks at the trs (white 
star) (B). A replication complex is assembled and replication commences through the TR towards the vector 
(C). The new synthesized ITR fold into a hairpin conformation displacing the replication strand. Such 
displacement determines a template switch so that the originally nicked strand is copied during replicat on. The 
replication passes through the other ITR and proceeds into the vector sequence (D). After replication frk has 
completed a full circle, Rep produces a second nick and the newly synthesized DNA is displaced as ssDNA 
(E). The new ssDNA is nicked again and two ssDNA containing only one complete ITR are formed (F). The 
missing ITR is repaired by gene correction mechanism (G). 
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This event involves the formation of a single stranded panhandle DNA intermediate in 
which both D elements are inverted and therefore can anneal to initiate the ITR repair 
synthesis (Fig. 3.9G) [273]. One ssDNA molecule has a complete ITR only at the 5’ end, 
while the other one carries ITR sequences without D element. If the ITRs do not fold into a 
hairpin conformation, the replication continues on the backbone vector sequences and the 
plasmid is completely replicated as observed in vitro [26];[274]. In this case the ITR is 
used as a cellular origin of DNA replication [274]. We also validated our model by 
determining the polarity of the ssDNA. By using specific ssDNA probes, we demonstrated 
the both the plus and the minus AAV strands are formed in yeast (Fig. 3.6D, E). Moreover, 
this study demonstrated that, in yeast, the ITRs represent the only sequences required for 
ssDNA AAV formation from an episomal plasmid (Fig 3.7A, B). Why does the yeast 
produce such high level of ssDNA? Is that due to an accumulation process of the newly 
formed ssDNA or is the mechanism leading to ssDNA formation more efficient in 
Saccharomyces cerevisiae than in human cells? The answer to these questions is not very 
easy but understanding which cellular factors are involved in the ssDNA formation may be 
crucial for AAV encapsidation. It is known that yeast is very efficient in DNA repair 
mediated by homologous recombination. Yalkinoglu et al. have shown that a plasmid 
containing the extreme left half of AAV with a single ITR could replicate in cells treated 
with genotoxic reagents suggesting a possible role of DNA damage repair in this process 
[275]. Moreover, in cultured human cells, a marked increase in rAAV transduction 
efficiency is obtained by treating cells with agents that affect genomic DNA integrity or 
metabolism, such as UV irradiation, hydroxyurea (HU), topoisomerase inhibitors and 
several chemical carcinogens [276-279]. It has been demonstrated recently that MRE11 
complex, which is primarily involved in DNA double strand break repair, binds the 
incoming ssAAV genome and poses a barrier to AAV and that the helper function 
provided by the adenoviral proteins E1b55K/E4orf6 involves the degradation of MRE11 
complex [72, 280]. These observations suggest that in human cells MRN complex can 
have a role in the rescue of AAV from plasmid. The igher efficiency of the non-
homologous end-joining apparatus in mammalian cells, related to the strong pressure to 
repair double-strand breaks in these large genomes, probably explains the ability of AAV 
to grow in these cells only when that apparatus is partially saturated by double-strand 
break events. This requirement is apparently not present in yeast that yet seemingly 
contains all the cellular factors necessary for AAV genome replication in the right balance. 
In yeast, double strand breaks are mainly repaired by homologous recombination so the 
MRN complex proteins are available for other processes and could be immediately 
engaged in ssDNA formation. The formation of ssDNA does not occur immediately after 
pAAV plasmid transformation and required the replication of the plasmid. In fact, we did 
not detect any ssDNA in yeast cells 3 or 24 hours after transformation (data not shown). 
Therefore, we can speculate that the formation of ssDNA initiates after the plasmid has 
been replicated. It could be interesting to study AAV ssDNA genome in yeast cells with 
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different genetic background. Thus, the utilization of this organism could allow not only to 
study the cellular requirements for viral production, but also, not less importantly, to 
overcome the present limitations in currently existing systems for commercial production 
of gene therapy used rAAV vectors; yeast, as a novel host, is safe, cheap and amenable to 
easy manipulation. 
We can thus conclude that the AAV genome can replicate in Saccharomyces cerevisiae; 
this is not surprising because yeast can replicate DNA genomes of numerous viruses, such 
as Human papillomavirus [213] and the ssDNA genome, Indian Mung Bean Yellow 
Mosaic virus [214].  
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4. To sum up… 
Taken together, the results of this work raise the importance of the budding yeast 
Saccharomyces cerevisiae both as a genetic system for studying various aspect  of AAV 
vector biology and as a biotechnological tool, a cell factory, for a potential production of 
AAV gene therapy vectors. Using the simplicity and plasticity of yeast molecular biology, 
in the first part of the work, we explored different strategies to induce the synthesis of 
AAV2 capsid proteins to a sufficient level and in the correct stoichiometry to promote 
capsid assembly. The presented results clearly demonstrate that the assembly process 
occurs, albeit not as efficiently as seen for many other viruses, stimulating further 
investigations toward finding better conditions and/or discovering novel assembly 
promoting factors that could meliorate the current state of art. Accordingly, we are 
currently investigating whether over-expression of AAV assembly activating protein 
(AAP) in yeast cells could give desired results. The second part of the work demonstrates 
that S. cerevisiae can form single stranded DNA AAV2 genomes starting from the circular 
plasmid. The model we propose for underlying mechanism differs greatly from what is 
seen in other AAV host cells. This, however, is notas surprising as it appears to be since 
what we currently know about AAV replication in the presence of different helper viruses 
is that this virus is able to adopt to the novel “rplication-supportive environment” in a way 
to optimally exploit the available replication factors. In this view, the genome-wide 
screening for the yeast cellular factors, regulating/being directly involved in the AAV 
replication, are the subject of future investigations.  In addition, we are currently focused 
on studying the way in which Adenoviral proteins, E4 orf6 and E1b55, increase the 
amount of ss AAV DNA formation, without significantly changing the pattern of other 
rAAV replicative intermediates. This research line should also reveal some yeast DNA 
repair proteins, potentially involved in the aforementioned process. Finally, a significant 
effort is to be put in studying the ability of yeast cell to support packaging of ss rAAV 




5. Materials & methods 
5.1. Strains, media, yeast transformation and cultivation 
Bacterial recombinants were screened in Escherichia coli XL10Gold cells.  
Two haploid, auxotrophic yeast strains were used, RSY12 and HT393. The “wild type” 
strain RSY12 (MATa leu2-3,112 his3-11,15URA3::HIS3) has a complete deletion of 
URA3 gene which was replaced with the HIS3 gene [281]. The “mutant” strain HT393 
(MATa leu2, ura3, pra1, prb1, prc1, cps1, pre1) is deficient in several proteases including 
parts of the proteasome, vacuolar proteases and metalloproteases [282]. 
Comparative protein expression analysis for all AAV2 proteins was done by transforming 
each of the following constructs independently in two yeast strains, RSY12 and HT393:  
1. 6 VP expressing: YEplacRepCap, YEplacp40Cap, Yep-Re78p40Cap, pYesCap, 
pYesIntronCap, pYesCap 
2. 3 Rep expressing: YEplacRepCap, Yep-Rep78p40Cap, pG.Rep68 
The same amount of plasmid DNAs were transformed into yeasts using the standard high-
efficiency, lithium chloride transformation method with single-stranded DNA as carrier 
[283]. Single transformants were selected onto SC-uracil (SC-URA) or SC-leucine (SC-
LEU) plates and the selection continued with the following growth in the corresponding 
liquid medium. 
Since no significant difference in relative protein VP/Rep expression levels was assessed 
by Western blot analysis for each strain couple of transformed constructs, for e.g between 
RSY12- YEplacRepCap and HT393- YEplacRepCap etc., only Western blot results 
obtained for RSY12 strain are presented in this work. Accordingly, all following 
cotransformation experiments for AAV particle production and purification, as well as for 
recombinant AAV vector genome replication studies used only RSY12 strain. Again, the 
same amount of plasmid DNAs were co-transformed into yeast using lithium chloride 
method. Cotransformed RSY12 cells were selected on SC-uracil-leucin (SC-URA-LEU) 
plates (and selection continued in the corresponding liquid medium). The frequency of 
URA3+LEU2+ colonies was calculated dividing the number of URA3+LEU2+ colonies by 
the number of LEU2+ total transformants. 
Complete (YPAD) and synthetic complete (SC) mediums were prepared according to the 
standards. Induction media were prepared with either 5% galactose or different glucose + 
galactose concentration as stated in the Results section of the chapter 2. 
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Yeast was cultivated aerobically, in flasks, at 30°C, under constant orbital shaking (180 
rpm). Different growth cycle experiments were started with a small volume inoculum (less 
than 100 µl per 50 ml of culture medium) of stationary phase yeast cells (grown for 24h 
from a single colony in 10 ml of SC) and cultivated overnight to obtain an early 
exponential (log) growth phase cell suspension of absorbance at 600 nm (O.D600) 0-7-1.0, 
equivalent to ~0.3 mg/ ml-’ cell dry weight. For mid-log phase cells were further grown to 
reach O.D600 3.5- 4.0 and for late-log/early stationary phase cell w re grown till optical 
density was ~8. If not processed immediately after th  grown cycle, cells were pelleted and 
stored at -70°C or liquid nitrogen frozen and then -70°C.  
The RSY12 clone with integrated copies of ADHRep68- expression cassette, was obtained 
by cell transformation with the SnaBI -ADHRep68-Leu- PvuII DNA fragment excised 
from pG.Rep68 plasmid [229] with SnaBI/PvuII enzymes. In this way, 2 micron sequence 
was eliminated in order to avoid autonomous replication upon putative recircularisation, 
while Leu was kept for selection of integrants.  
5.2. Plasmid construction 
All AAV2 sequences in the following constructs deriv  from pSub201 plasmid which 
contains complete wild-type AAV-2 genome cloned into a plasmid backbone [19].  
pYEplac181(Leu2), pYes2(Ura3) and pGAD 424(Leu2) are three commercially available, 
yeast-cell compatible vectors with ura3/leu2 genes for selection in yeast . 
Constructs with pYEplac181vector backbone: 
For construction of the pYplacRepCap plasmid entire AAV2 genome without ITRs was 
cut out from pSub201, using Xba I sites for digestion, and placed in the same restriction 
site of the pYEplac181 vector. For construction of the pYplacp40Cap lasmid, unmodified 
AAV2 Cap gene was cut out from pSub201 using Sal I and Xba I sites and cloned in the 
same sites of YEplac181 vector. To make the Yep-Rep78p40Cap plasmid, ADHRep78 
expression cassette was excised from pG.Rep78 plasmid [229], using flanking SphI sites 
and cloned upstream of Cap ORF in Sph I site of pYplacp40Cap. 
The plasmids pGAD424, pG.Rep78 and pG.Rep68 were kindly provided by M. D. 
Weitzman [229]. The pG.Rep78 and pG.Rep68 construct contain Rep68cDNA and 
Rep78cDNA, respectfully, downstream of the constitutive yeast promoter ADH1 in 
pGAD424 plasmid backbone. 
Cloning in the pYes2 expression vector, downstream of inducible yeast promoter, 
Gal1: 
For construction of the pYesIntronCap plasmid, AAV2 Intron + Cap ORF sequence 
(without p40 promoter) was cut out from pSub201 using HindIII and XbaI restriction sites 
and cloned in the same sites comprised in the multiple cloning site of pYes2 vector. 
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For construction of the pYesCap plasmid, VP1 cDNA(comprising all three overlapping VP 
cDNAs)  (map positions 2203-4410 in wild-type AAV2 genome in the database, GenBank 
accession no. AF043303.1) was PCR amplified from pSub201 using following primers:  
5' - ctt ATGGCTGCCGATGGTTATCTT-3' and  
5' - ctggTTACAGATTACGAGTCAGGTA -3' 
The sequence corresponding to the wild-type AAV2 genome is capitalized. PCR product 
was polyA tailed to enable compatible end ligation with polyT tailed intermediate vector 
pGEM®-T Easy (Promega Corporation). After ligation, PCR clones were sequenced and 
the correct VP sequence was NotI excised from the pGEM®-T Easy and cloned into NotI 
site of pYes2 MCS. 
The pYesVP1K.M plasmid was constructed by cloning modified VP1 cDNA under Gal1 
promoter. The VP1cDNA was PCR amplified from pSub201vecotr using following 
primers:  
5'-caggatccaaacaATGGCTGCCGACGGTTATCTACCCGATTGGCTC-3' and  
5'-ccggatccTTACAGATTACGAGTCAGGTATCTGGTGC-3'.  
Bam HI sites (at each primer end, underlined and bolded etters) were introduced outside 
the VP1 expression cassette for cloning in pYes expression plasmid. Beside Bam HI 
restriction site, upper primer also included 6 nucleotide long yeast Kozak sequence 
(italicized letters) upstream of the VP1 ATG and three modifications (underlined letters) 
relative to the genuine VP sequence in the database. The sequence corresponding to the wt 
VP ORF is capitalized. After direct cloning in pYes2 Bam HI site desired clone contained: 
Kozak sequence upstream of ATG start site and three mutations with respect to genuine 
AAV2 sequence. The first T to C mutation at position 11 eliminates an out-of frame ATG 
codon by creating an ACG triplet instead. The second modification is inactivation of the 
major AAV splice acceptor site, by substituting T to A at position 21 and A to C at 
position 24 (numbering is as for the seq. in the datab se) 
Construction of vectors containing recombinant AAV genome: 
The plasmids pAAVRepURA3 and pAAVpokURA are derivates of pSub201 plasmid.  
The pAAVRepURA3 plasmid maintains the entire rep gene and has an internal deletion of 
cap gene. The URA3 marker gene, excised from pMA150 vector by using BamHI sites for 
restriction digestion [284], was cloned in the blunt ApaI/KpnI sites of pSub201 after filling 
in with Klenow polymerase. The pAAVpokURA contains only the URA3 gene and a 
stuffer sequence in order to increase the distance between ITRs. The stuffer sequence, 
named pok, consists of 2.5kb-long mouse pokemon gene. pAAVpokURA was made by 
cloning the pok sequence and URA3 gene (pMA150 derived) in pMCSsub vector. The 
pMCSsub was constructed by substituting the multiple cloning site of the pCMV-MCS 
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vector (Stratagene, La Jolla, CA,USA) with a multiple cloning site containing NotI XbaI 
XhoI EcoRI BamHI HindIII SalI XbaI NotI. The URA3 gene was cloned in the HindIII 
site of pMCSsub, obtaining pMCSsubURA. The pok sequence was cloned in XhoI and 
EcoRI sites of pMCSsubURA obtaining pMCSubpokURA. Pok and URA3 were then cut 
out with XbaI and cloned in XbaI site of pSub201. 
The pRepURA plasmid was constructed by XbaI digestion of the pAAVRepURA plasmid 
to eliminate ITRs, and cloning the XbaI-RepURA-XbaI fragment in XbaI site of 
pMCSsub. 
To obtain the plasmid pEsc-G418, LEU2 selection marker of the commercial vector pEsc-
Leu (Stratagene) was substituted with the gene Kan-MX, whose product provide the 
transformed cells resistant to antibiotic G418.  Kan-MX (~ 1500 bp) was cut out from 
another comercial plasmid pYMN1 (Euroscarf) using EcoRV and PstI restriction sites and 
cloned in EcoRV and BsteII (isoschizomero di PstI) ites of pEs-Leu. The mentioned 
digestion of the pEsc-Leu resulted in elimination of approx 700bp of LEU2 gene fragment 
causing its inactivation. 
The gene E4orf6 was amplified by PCR from pDG plasmid [94], using following primer 
pairs: 
5‘CTAGGATCCATGACTACGTCCGGCGTT 3’ and  
5‘CTAGTCGACCATGGGGGTAGAGTCATA 3’ 
Restriction sites Bam HI and Sal I ( at each 5’ primer end, respectively; shown in 
underlined and bolded letters) were introduced outside the E4orf6 expression cassette for 
cloning in respective sites in pESC-G418 expression plasmid, downstream of Gal1 
promoter. 
The gene E1b55k was amplified by PCR from genomic DNA derived from 293T cells 
using following primer pairs: 
5‘ACTGCGGCCGCATGGAGCGAAGAAACCCATC 3’ and  
5‘ TTAACTAGT CCATCTGTATCTTCATCGCTAGA 3’ 
Restriction sites NotI and SpeI ( at each 5’ primer end, respectively; shown in underlined 
and bolded letters) were introduced outside the E1b55k expression cassette for cloning in 
respective sites in pESC-G418 expression plasmid, downstream of Gal10 promoter and in 
frame with tag FLAG ORF. 
5.3. RNA isolation and Retro-Transcription  
Total yeast RNA was extracted from 5 x 107 of actively growing cells (grown to early log 
phase) following the method published by Schmitt et al. [285]. 3 µg of total RNA was 
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retrotranscribed using QuantiTect Reverse Trascription Kit of Qiagen (using oligo-dT 
primers) according to the manufacture’s recommendations. Resulting cDNA was subjected 
to PCR amplification using following pair of primers:    
5’-AGTTGCGCAGCCATCGACGT-3’ and 5’-TGGCTGTCCGAGAGGCTG- 3’ 
PCR products were analyzed upon 5% acrilamide gel-electrophoresis, for separation of 
nucleic acids less than 1000 bp in length, and visualized by Etidium-Bromide (EtBr) 
staining. 
5.4. Analysis of protein expression. 
For analysis of protein expression by gel electrophoresis, total cellular polypeptides were 
obtained by means of two different extraction methods:  
1. Glass-bead based cell rupture followed by separation of soluble and insoluble protein 
fraction: 10 millions of cells grown till mid-expone tial growth phase were harvested, 
washed and resuspended in the disruption buffer  DB (30 mM Tris-HCl, pH 7.8, 2 mM 
EDTA, 0.5% Triton X-100, 1 mM PMSF; proteinase inhibitors cocktail added) and 
disrupted with equal volume of glass beads (400 nm diameter). Disruption at 4°C was 
performed by 10 cicles of 30’ vortex + 30’ ice incubation. Crude lysates were cleared by 
centrifugation (2000xg for 5 min, 4°C). The insoluble protein fraction was separated from 
soluble one by another centrifugation (10,000×g, 40 min, 4 ◦C). Insoluble proteins, from 
the pellet, were extracted twice in the extraction buffer (DB exempted of EDTA and 
supplemented with 1%SDS and 1%DOC) for 1 h at 4 ◦C agitation. 
2. “Optimized post-alkaline extraction”  method consists of two cycles of protein 
extraction. 100-200 x 106 of actively growing yeast cells were pelleted and subjected to the 
first round of extraction by the method published by Kushnirov [230]. Briefly, cells were 
pelleted and shortly exposed to mild alkali conditions (0.1M NaOH) and lysed by heat at 
95°C for 5 min in 50µl of 1x SDS-PAGE loading buffer  (4x buffer: 150mM TrisHCl 
pH6.8, 50% glycerol, 10% SDS, 10% β-mercaptoethanol, 0.06% bromophenol blue). After 
eliminating cellular debris by centrifugation, the first protein extract named “first extract” 
was ready for analysis by gel electrophoresis. For the “second extraction”, cellular debris 
was treated with a variant of a standard harsh RIPA buffer (500mM NaCl, 50mM Tris-
HCl, 1mM EDTA, 1% Triton, 1% DOC, 1% SDS) and put forward to a quick sonication 
(Soniprep 150). Precisely, the remaining pellet wasresuspended in 140 µl of RIPA buffer 
(proteinase inhibitors added), incubated on ice for 20 min and then for another 20 min on 
the rotation at 4°C. After sonication (5 cycles of 10 seconds on and 20 seconds off; 15 
microns amplitude), the second protein fraction, named “second extract” (insoluble 
aggregates), was separated from remaining cellular impurities by quick centrifugation and 
analyzed by gel electrophoresis.  
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Proteins were resolved on 10% polyacrylamide gel in SDS–Tris–glycine buffer. 
Following SDS-PAGE proteins were electro-transferred to Hybond-C Extra nitrocellulose 
membrane (Amersham Biosciences, UK) in methanol-Tris glycine buffer. The blots were 
blocked with: 1) 10% milk or 2) 5% in TBS-T (Tween 0.1%) for 1 h and then, 3) 6 3% 
milk 1%BSA in PBS 1x for 1 h, 4) 5% milk in TBST overnight. After blocking blots were 
incubated overnight at 4°C with the following primary antibodies: 1) anti-Rep monoclonal 
mAb 303.9, anti.VP1,2 mAb A69 and anti-capsid mAb A20. All named antibodies were  
diluted 1:50 in TBS-T with 5% milk;  2) anti-VP1,2,3 diluted 1:200 in 2.5% milk TBS-T. 
All listed Abs are from Progen Biotechnik GmbH, Heid lberg, Germany. For detection of 
the protein E4orf6 we used 3) mAb-Anti E4orf6 diluted  1:20 in PBS solution 
supplemented with 3% milk and 1%BSA (a kind gift from D. Ornelles). Incubation was 
done overnight. For detection of E1b55k we used 4) mAb anti-Flag (Sigma) diluted 1:1000 
in  TBST-5% milk and incubated for 1h, room temperature (RT). For loading control the 
same blots were incubated for 1h with primary mouse antibody anti-3 phosphoglycerate 
kinase (3PGK, Molecular Probes) diluted 1:5000 in 1% milk in TBS-T. Secondary 
antibodies conjugated to horseradish peroxidase (IgG-HRP) (Santa Cruz Biotechnology, 
Inc.) were used for detection of specific antibody binding (diluted 1:2500 in the same 
solution of the corresponding primary antibody). The blots were stained with the Super 
Signal West Femto chemiluminescent substrate (Thermo Fisher Scientific, Inc.). 
5.5. AAV VLP extraction and purification  
For this purpose actively growing 25ml 2% glucose culture was diluted in 250 ml and re-
grown  on glucose for another 12-16h until reached OD600 4 (mid-log phase). At this point 
the cells were collected and the media replaced with 1l of induction media (0.5% Glu+5% 
Gal). After 4.5 h cells were harvested and subjected to disruption:  
Mechanical lysis under non-denaturizing conditions: 10g of yeast dry biomass was 
resuspended in 20ml of DNS disruption buffer of following composition: 500mM NaCl, 
10mMTris(pH8), 1mM EDTA, 0.3% NP-40, 0.3% deoxycholate (DOC), supplemented 
with protease-inhibitor cocktail  and homogenized in the presence of 400nm glass beads 10 
cycles of 40sec vortex-homogenization. The crude lysate was cleared from cell-debris and 
undisrupted cells by quick-low speed centrifugation. After clearance, the crude lysate was 
subjected to 1h high speed centrifugation (20 000 x g), which was followed by the second 
extraction from the obtained pellet. The second extraction was performed in the same way 
as the first one with additional sonication step to enhance solubilization of yeast produced 
AAV VLPs. This was done in 10 sonication cycles (Soniprep 150; 15sec on and 30sec off; 
15microns amplitude). After sonication the cell lysate was centrifuged again for 1h at 
20000g at 4°C. This extended clearance was supposed to eliminate most efficiently 
aggregated, insoluble material. The resulting, second extract (supernatant), was united with 
the first extract and subjected to 200,000 x g, 3h ultracentrifugation through 40% sucrose 
80 
cushion (40% sucrose in TE-BSA buffer: 10mM Tris pH8, 1mM EDTA and 0.01%BSA). 
After the centrifugation, AAV particle-containing sediment was resuspended in 5ml 
Resuspension Buffer of physiological salts concentrations (150 mM NaCl, 10 mM Tris-
HCl pH 8, 1 mM EDTA, 5 mM MgCl2), quickly sonicated and left in agitation for 15 h at 4 
°C. To improve solubilisation of assembly products, it was further subjected to 30min 37C 
DNase digestion (purity grade I, Benzonase, Novagen), stopped by 10mM EDTA. For 
digestion, MnCl2 and MgCl2 were added the extract to 1mM final concentrations. At the 
end, extract was cleared from aggregated material by 10 min, 15000 x g centrifugation at 
4°C and supernatant was loaded on CsCl gradient for AAV VLPs purification. CsCl was 
added to the sample at final density of 1.4 g/cm3, and ultracentrifugation was performed in 
a SW40-Ti rotor (48 h, 39,000 rpm, 18°C; ultracentrifuge). 13 fractions of 1.371 to 1.430 
g/cm3 densities (refractometer readings) were colleted, dialyzed against PBS buffer, and 
each fraction was analyzed for VP composition by Western blot. Fractions with similar 
densities were united and analyzed by negative staining electron microscopy. 
5.6. Transmission electron microscopy  
After purification by CsCl centrifugation suspensions of yeast-produced AAV VLPs were 
placed on 400-mesh carbon coated grids. The sample was stained with five drops of 2.5% 
(w/v) of uranyl acetate solution and incubated for 2 minutes at room temperature. The 
excess solution was removed by blotting the edge of ach grid onto filter paper and the 
grid was air dried  for 30 minutes. Samples were examined with a Jeol 100 SX 
transmission electron microscope with 80000 magnification. 
5.7. DNA isolation and Southern blotting 
Genomic DNA was isolated using the Master pure yeast DNA purification Kit (Epicentre 
Biotechologies). Low molecular weight (Mr) DNA was isolated from 5 to 10 
independent URA3+LEU2+ clones harboring the AAV genome by using the yeast plasmid 
miniprep kit (Zymo Research Orange, CA) as previously reported [286]. The DpnI 
resistance assay was performed to check that the plasmid had replicated in yeast. When the 
plasmid DNA is replicated and methylated by bacteria, it becomes sensitive to DpnI 
digestion and it is thus distinguishable from DNA synthesized in eukaryotic cells which is 
not methylated and, therefore, resistant to digestion [287]. By contrast, MboI recognizes 
the same sequence as DpnI, but cuts only DNA not methylated. The DNA samples were 
digested with DpnI or MboI for 24 h and loaded on 1% agarose gel. The DNA was 
electrophoresed, transferred to nylon membrane (Roche) and probed with DIG-labelled 
URA3 obtained by PCR from the plasmid YEplac211 with following primers: 
pURA-R 5’GATACCCGGGACCTGACGTCTAAG3’ and 
 pURA-F 5’ACATCCCGGGTGACGGGCTTGTCTGCTCCC3’.  
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The ITR probe was obtained by DIG random primed labelling kit (Roche) using as 
template gel purified ITRs obtained digesting pSub201 with XbaI and PvuII. To determine 
the presence of the plasmid backbone, we also constructed the F1 probe that was obtained 
by PCR performed with nucleotide mix containing DIG-dUTP from pSub201 plasmid with 
the following primers:  
F1 forward: 5’CAA CCA TAG TAC GCG CCC 3’;  
F1 reverse: 5’ CAA TAA ATC ATA CAG GCA AGG 3’. 
To determine the polarity of ssDNA we used two synthetic oligonucleotides of 100 mer 
as probe (IDT integrated DNA technologies). The probe for the plus (+) strand, named 
URA(+) has the following sequence: 
5’CTTCCAACAATAATAATGTCAGATCCTGTAGAGACCACATCATCCACGGTTC
TATACTGTTGACCCAATGCGTCTCCCTTGTCATCTAAACCCACACCGG 3’.  
To determine the presence of the minus (-) strand, we used the synthetic URA(-) probe 
with the following sequence: 
5’CCGGTGTGGGTTTAGATGACAAGGGAGACGCATTGGGTCAACAGTATAGAA
CCGTGGATGATGTGGTCTCTACAGGATCTGACATTATTATTGTTGGAAG 3’.  
The probes were labeled using the DIG oligonucleotid  3’-End Labeling kit, 2nd 
generation (Roche), according to manufacturer’s instructions. Equal amount of DNA was 
loaded on two gel slots, electrophoresed and transferred on nylon membrane positively 
charged (Roche). Since the 3’end labeled oligonucleotid  probes are less sensitive than the 
PCR labeled probes, we hybridized only the ssDNA to increase the signal. 
S1 and Mung Bean reaction 
To identify the presence of ssAAV genome, low Mr DNA samples were digested with S1 
nuclease (Promega) or Mung Bean Nuclease (New England Biolabs) which cut only 
ssDNA. Briefly, 10µl of low Mr DNA were digested with 0.1U of S1 nuclease for 30 min 
at 37°C in the provided buffer and inactivated at 70°C for 10 min. For Mung Bean 
Nuclease, 10µl of low Mr DNA were digested with 0.1 U of Mung Bean for 30 min at 
37°C in the provided buffer. The reaction was stopped with STOP solution (5mM EDTA, 
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